US20210364515A1 - Optimizing diagnostics for galactofuranose containing antigens - Google Patents
Optimizing diagnostics for galactofuranose containing antigens Download PDFInfo
- Publication number
- US20210364515A1 US20210364515A1 US17/388,733 US202117388733A US2021364515A1 US 20210364515 A1 US20210364515 A1 US 20210364515A1 US 202117388733 A US202117388733 A US 202117388733A US 2021364515 A1 US2021364515 A1 US 2021364515A1
- Authority
- US
- United States
- Prior art keywords
- seq
- species
- sample
- sub
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 79
- AVVWPBAENSWJCB-RSVSWTKNSA-N D-galactofuranose Chemical compound OC[C@@H](O)[C@@H]1OC(O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-RSVSWTKNSA-N 0.000 title claims abstract description 34
- 102000036639 antigens Human genes 0.000 title abstract description 76
- 108091007433 antigens Proteins 0.000 title abstract description 76
- 239000000523 sample Substances 0.000 claims abstract description 114
- 238000000034 method Methods 0.000 claims abstract description 100
- 210000002700 urine Anatomy 0.000 claims abstract description 73
- 238000001514 detection method Methods 0.000 claims abstract description 63
- 208000015181 infectious disease Diseases 0.000 claims abstract description 60
- 230000000813 microbial effect Effects 0.000 claims abstract description 58
- 230000027455 binding Effects 0.000 claims abstract description 57
- 239000012472 biological sample Substances 0.000 claims abstract description 44
- 241000228212 Aspergillus Species 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims abstract description 9
- 241000228402 Histoplasma Species 0.000 claims abstract description 9
- 241000223218 Fusarium Species 0.000 claims abstract description 8
- 230000002538 fungal effect Effects 0.000 claims abstract description 8
- 241000223203 Coccidioides Species 0.000 claims abstract description 7
- 241000222722 Leishmania <genus> Species 0.000 claims abstract description 7
- 244000052769 pathogen Species 0.000 claims abstract description 7
- 230000001580 bacterial effect Effects 0.000 claims abstract 2
- 230000003071 parasitic effect Effects 0.000 claims abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 55
- 101001050473 Homo sapiens Intelectin-1 Proteins 0.000 claims description 37
- 102000044725 human ITLN1 Human genes 0.000 claims description 36
- 150000004676 glycans Chemical class 0.000 claims description 33
- 229920001282 polysaccharide Polymers 0.000 claims description 25
- 239000005017 polysaccharide Substances 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 238000002965 ELISA Methods 0.000 claims description 22
- 239000000758 substrate Substances 0.000 claims description 22
- 238000011033 desalting Methods 0.000 claims description 13
- 206010017533 Fungal infection Diseases 0.000 claims description 11
- 101710126866 Intelectin Proteins 0.000 claims description 11
- 208000031888 Mycoses Diseases 0.000 claims description 11
- 230000009471 action Effects 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 11
- 238000003745 diagnosis Methods 0.000 claims description 7
- 238000003118 sandwich ELISA Methods 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 5
- 150000001768 cations Chemical class 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 239000004816 latex Substances 0.000 claims description 5
- 229920000126 latex Polymers 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000007246 mechanism Effects 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- AVVWPBAENSWJCB-DGPNFKTASA-N beta-D-galactofuranose Chemical compound OC[C@@H](O)[C@@H]1O[C@@H](O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-DGPNFKTASA-N 0.000 abstract description 72
- 101150060566 galF gene Proteins 0.000 abstract description 56
- 238000003556 assay Methods 0.000 abstract description 51
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 241000193998 Streptococcus pneumoniae Species 0.000 abstract description 5
- 229940031000 streptococcus pneumoniae Drugs 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 4
- 102100023353 Intelectin-1 Human genes 0.000 abstract description 3
- 230000000890 antigenic effect Effects 0.000 abstract description 3
- 101710112297 Intelectin-1 Proteins 0.000 abstract description 2
- 239000012528 membrane Substances 0.000 description 33
- 239000012491 analyte Substances 0.000 description 31
- 238000012360 testing method Methods 0.000 description 31
- 239000012530 fluid Substances 0.000 description 22
- 239000007788 liquid Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 15
- 230000008685 targeting Effects 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 239000011575 calcium Substances 0.000 description 12
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000012085 test solution Substances 0.000 description 11
- 239000000020 Nitrocellulose Substances 0.000 description 10
- 238000004891 communication Methods 0.000 description 10
- 229920001220 nitrocellulos Polymers 0.000 description 10
- 201000002909 Aspergillosis Diseases 0.000 description 9
- 208000036641 Aspergillus infections Diseases 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000002738 chelating agent Substances 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 239000002250 absorbent Substances 0.000 description 8
- 230000002745 absorbent Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- -1 Ca2+ ions Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 241000194017 Streptococcus Species 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 239000004005 microsphere Substances 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 239000000123 paper Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 241000186046 Actinomyces Species 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 241001225321 Aspergillus fumigatus Species 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000187654 Nocardia Species 0.000 description 5
- 241000589516 Pseudomonas Species 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000223104 Trypanosoma Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- YPZMPEPLWKRVLD-PAMBMQIZSA-N (2r,3s,4s,5r,6s)-2,3,4,5,6,7-hexahydroxyheptanal Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O YPZMPEPLWKRVLD-PAMBMQIZSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- YPZMPEPLWKRVLD-UHFFFAOYSA-N L-glycero-D-manno-heptose Natural products OCC(O)C(O)C(O)C(O)C(O)C=O YPZMPEPLWKRVLD-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229960003082 galactose Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 229920000926 Galactomannan Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CVRXLMUYFMERMJ-UHFFFAOYSA-N N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CCN(CC=1N=CC=CC=1)CC1=CC=CC=N1 CVRXLMUYFMERMJ-UHFFFAOYSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000007818 agglutination assay Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- FJEKYHHLGZLYAT-FKUIBCNASA-N galp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)[C@@H](C)O)C(C)C)C1=CNC=N1 FJEKYHHLGZLYAT-FKUIBCNASA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 241000258957 Asteroidea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 241001135524 Legionella anisa Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000003017 in situ immunoassay Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000012092 latex agglutination test Methods 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000013197 protein A assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000012129 rapid antigen test Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56961—Plant cells or fungi
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- Galactopyranose the 5-member ring form of galactose
- Galactofuranose the 5-member ring form of galactose
- Equilibrium strongly favors the galP form unless the organism contains specific enzymes to catalyze maintenance of galF.
- galF is an important residue on glycoconjugate antigens, and can be found linked to secreted and cellular polysaccharides, glycoproteins and glycosphingolipids.
- introduction of galF is via inhalation and pulmonary introduction.
- the present inventors previously identified a class of antibodies that were generated against conidia of an important fungal pathogen, called Aspergillus fumigatus . These antibodies were found to identify galF—containing antigens that were quickly excreted in urine after infection in mammals. The antibodies and the technology enable their use as a urine diagnostic assay.
- the present invention provides methods for improved galF antigen detection in human body fluids by disabling or otherwise removing a competitive inhibitor, the human lectin, intelectin-1 from the assay process previously disclosed in U.S. patent application Ser. No. 13/511,264, and incorporated by reference herein in its entirety.
- intelectin is known to be secreted by epithelial cells lining the GI tract and respiratory tract, and for recognizing galF antigens, intelectin was not known until now to be present in urine.
- the present inventors surprisingly determined that intelectin is also present in urine, and serves to compete with galF-directed antibodies when they are used as part of diagnosing microbial infections in a mammalian subject. Though not wishing to be bound by the following theory, it is thought that this inhibition or interference is dependent on calcium, which can be removed by chelation as a mechanism to optimize antigen identification.
- the microbial infection is caused by an organism selected from the group consisting of Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, and Histoplasma species.
- the microbial infection is caused by Prokaryotic and Eukaryotic pathogens that produce galF-containing antigens, including but not limited to, Streptococcus species, Pseudomonas species, Nocardia species, Actinomyces species. Zygomycetes and parasites, including but not limited to Leishmania species, and Trypanosoma species.
- the present invention provides methods for optimization of galF-antigen identification in fluids that contain intelectin, including urine, respiratory fluids, gastrointestinal fluids, and blood.
- intelectin including urine, respiratory fluids, gastrointestinal fluids, and blood.
- the present inventors found that this is important for optimizing those methods that specifically focus on fungal antigens.
- the utility is broadly applicable to diagnostics that target galF containing antigens in many different diagnostic systems, given the ubiquity of galF in microbial antigens.
- the present invention provides a method for diagnosing a microbial infection in a biological sample from a mammalian subject suspected of having, having, or susceptible to having a microbial infection by detecting the presence of at least one microbial molecule comprising a galactofuranose (galF) residue (for example, glycoprotein, polysaccharide or sphingolipid) in a biological sample of the mammalian subject, the method comprising: (a) treating the biological sample to decrease human intelectin (hIntL) binding of galF residues present in the sample; (b) allowing the treated sample of (a) to come in contact with at least one antibody specific for at least one molecule comprising a galF residue in an effective amount to produce a detectable amount of antibody-galF complex; and (c) detecting the presence of at least one antibody-galF complex, wherein the detection of the presence of at least one antibody-galF complex is diagnostic of a microbial infection in a mammalian subject.
- galF galactofura
- the present invention provides a method for diagnosing a microbial infection in a biological sample from a mammalian subject suspected of having, having, or susceptible to having a microbial infection by detecting the presence of at least one antigen comprising a galF residue in a biological sample of the mammalian subject, the method comprising: (a) treating the biological sample comprising contacting the sample with a substrate such as a ligand which binds directly to intelectin, or calcium or divalent cations with high affinity, thereby inhibiting or interfering with human intelectin (hIntL) binding of microbial molecule containing galF residues present in the sample; (b) contacting the treated sample of (a) with at least one antibody specific for at least one molecule comprising a galF residue in an effective amount to produce a detectable amount of antibody-galF complex; and (c) detecting the presence of at least one antibody-galF complex, wherein the detection of the presence of at least one antibody-galF
- the method for treating the sample in step (a) comprises contacting the sample with a substrate which binds Ca′ ions with high affinity.
- the method for treating the sample in step (a) comprises contacting the sample with a compound which chelates Ca 2+ ions with high affinity.
- the method for treating the sample in step (a) comprises contacting the sample with EDTA and/or EGTA.
- the method for treating the sample in step (a) comprises contacting the sample with a substrate which binds hIntL with high affinity.
- the method for treating the sample in step (a) comprises contacting the sample with an antibody specific for hIntL.
- the method for treating the sample in step (a) comprises contacting the sample with one or more compounds which are bound by hIntL with high affinity, thereby preventing galF-binding to hIntL.
- the method for treating the sample in step (a) comprises contacting the sample with one or more compounds which are bound by hInL with high affinity selected from the group consisting of glycerol, 3-Keto-2-deoxyoctonic acid; D-glycerol-1-phosphate, D-mannoheptose, sepharose, sepharose-containing particles (i.e. latex, polystyrene or glass beads, microspheres or gels).
- glycerol 3-Keto-2-deoxyoctonic acid
- D-glycerol-1-phosphate D-mannoheptose
- sepharose sepharose-containing particles (i.e. latex, polystyrene or glass beads, microspheres or gels).
- FIG. 1 illustrates the inventors' prior discovery of galF antigens in the urine of patients with Aspergillus infection and production of monoclonal antibodies specific for galF antigens, with sensitivity to detect excreted antigens in urine samples.
- FIG. 2 shows intelectin and what is known about lectin molecules.
- FIG. 3 shows the inventors' hypothesis that hIntL was secreted into the urine and was competitively binding to galF antigens in the presence of the inventors' monoclonal antibodies specific for galF, and that desalting removes Ca 2+ needed for hIntL to bind galF.
- FIGS. 4A-4B depict (A) recombinant hIntL-1 binds to Aspergillus ethanol precipitate (EP) in an ELISA, and (B) binds to whole cells (conidia and hyphae).
- EP Aspergillus ethanol precipitate
- FIG. 6 shows that urine from a patient with invasive Aspergillus infection (aspergillosis) contains a different conformation of hIntL than healthy control urine.
- Radiograms from Western blots show that the aspergillosis patient urine contains small molecular weight bands which migrate at sizes consistent with subunits of the hIntL-1 heterotrimer protein. Healthy patient urine contains a single 120 kDa band of hIntL, consistent with the intact heterotrimer.
- FIG. 7 shows that galF specific antibody mAB476 binds to the band that co-migrates with that recognized by anti-hIntL and shows that when the aspergillosis patient urine is desalted prior to contacting the urine with the antibody, the amount of antibody binding is increased. Desalting also appears to affect the hIntL heterotrimer protein as more of it is found in small molecular weight bands which are the subunits of hIntL.
- FIG. 8 depicts small to medium molecular weight proteins on SDS-PAGE gel probed with mAB476 at a 1:1000 titer and detected with goat-anti-mouse IgM-HRP at a titer of 1:10,000.
- the mAB476 antibody binds to these small molecular weight moieties in aspergillosis patient urine, but not in healthy patient urine; these are the galF-containing antigens that are released by the microbe.
- FIG. 9 shows localization of mAB476 antibody-reactive bands relative to the anti-hIntL antibody reactive bands.
- FIG. 10 depicts a reducing SDS-PAGE gels of concentrated urine from healthy (pool 4) and patient (VU7), both normal and desalted, were run and stained with Sypro-Ruby fluorescent protein stain. The small to mid-range molecular weight bands were cut out of the gels and prepared for mass spectrometry analysis.
- FIG. 11 shows graphs depicting immunoprecipation assays using mAB476 in urine samples of urine samples, both normal and desalted.
- urines were incubated with superparamagnetic dynabeads coated with mAB476 and a mouse control antibody.
- mAB476 reactive material was eluted with 50 mM glycine (pH 2.5-3.0). No mAB476 binding occurred in normal urine.
- Reactivity to mAB476 eluates was confirmed by sandwich ELISA. Eluates were then run on SDS-PAGE gels to check for band patterns, and in-solution mass spectrometry analysis was performed. Analysis detected both the microbial antigen CelA/Aspf7 (a galF-containing 0-glycan), and the human hIntL protein ( FIG. 12 ).
- FIGS. 13 and 14 show that treatment of the patient urine with calcium chelators or other compounds which bind calcium or compete with galF for hIntL-1 binding with high affinity, when added prior to contacting the sample with galF antibodies, significantly improves detection sensitivity.
- Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of polysaccharide antigenic components utilizing monoclonal antibodies.
- the methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galF antigens and improvement of sensitivity of galF antigen detection assays.
- the methods include minimizing hIntL binding to galF antigens and improvement of monoclonal antibody binding.
- the detection methods are useful for identifying the presence of microbial antigens related to Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, and Histoplasma species.
- the microbial infection is caused by Prokaryotic and Eukaryotic pathogens that produce galF-containing antigens, including but not limited to, Streptococcus species, Pseudomonas species, Nocardia species, Actinomyces species. Zygomycetes and parasites, including but not limited to Leishmania species, and Trypanosoma species.
- Intelectin was previously called ‘omentin’ as it is secreted from adipose cells and epithelial cells. Intelectin binds to molecules that contain sugar residues (such as galF), especially those produced by microbes and other non-mammalian organisms (ex. algae, plants). Intelectin is thought to be involved in host-defense as it is produced by epithelial cells facing the environment, such as those lining the airways and gut.
- sugar residues such as galF
- the antibody of the presently disclosed methods is, in some aspects, specific for at least one antigen containing a galactofuranose residue and is selected from the group consisting of monoclonal antibody 205 (MAb 205) comprising a variable heavy (VH) domain of SEQ ID NO:1 and a variable light (VL) domain of SEQ ID NO:2; monoclonal antibody 24 (MAb 24) comprising a VH domain of SEQ ID NO:3 and a VL domain of SEQ ID NO:4; monoclonal antibody 686 (MAb 686) comprising a VH domain of SEQ ID NO:5 and a VL domain of SEQ ID NO:6; monoclonal antibody 838 (MAb 838) comprising a VH domain of SEQ ID NO:7 and a VL domain of SEQ ID NO:8; and monoclonal antibody 476 (MAb 476) comprising a VH domain of SEQ ID NO:9 and a VL domain of SEQ ID NO:10.
- the presently disclosed subject matter provides a lateral flow device adapted to perform the presently disclosed methods for diagnosing a microbial infection in a biological sample of a mammalian subject suspected of having, having, or susceptible to having a microbial infection.
- presently disclosed subject matter provides a dipstick assay to perform the presently disclosed methods for diagnosing a microbial infection in a biological sample of a mammalian subject suspected of having, having, or susceptible to having a microbial infection.
- the presently disclosed subject matter provides an antibody specific for at least epitope of an antigen secreted by a microbial organism, wherein in particular aspects, the antigen comprises a galactofuranose residue.
- Point-of-Care Diagnostics Such as Lateral Flow Devices and Dipstick Assays: Theory and Current Applications
- POC test devices in common use today include pregnancy and fertility tests, as well as assays to follow blood glucose in diabetics. Development of diagnostic tests for infections that use POC testing are especially important in resource-poor settings; for this reason, POC testing has become a new goal to be achieved for infections such as HIV, malaria, and hepatitis. Similarly, POC testing has the potential of impacting clinical outcomes when applied to infections that occur in the outpatient setting, not only by providing indications of disease, but by enabling development of more robust prevention algorithms.
- ELISAs enzyme-linked immunosorbent assays
- mAbs monoclonal antibodies
- mAbs monoclonal antibodies
- Various approaches have been described for carrying out enzyme immunoassays. A considerable number of these approaches, starting with the earliest of ELISAs, are solid-phase immunoassays in which the analyte to be detected is bound to a solid matrix directly (Direct ELISA) or indirectly (Sandwich ELISA), in which the analyte is captured on a primary reagent. The choice of the solid matrix depends on procedural considerations.
- a common matrix is the polystyrene surface of multi-well microtiter plates.
- LFD lateral-flow device
- the reagent components are added in a dried state so that fluid from the sample re-hydrates and activates them.
- Conventional ELISA techniques can then be used to detect the analyte in the antigen-antibody complex.
- the system can be designed to provide a colorimetric reading for visual estimation of a binary response (‘yes’ or ‘no’), or it can be configured to be quantitative.
- Lateral flow devices are used to detect analytes in multiple body fluids, including serum and urine. To date, these types of devices have seen the most use for detecting circulating endogenous analytes; perhaps the most common use of this type of device is in the ubiquitous POC pregnancy test.
- Current efforts are being directed toward detecting microbial analytes, including nucleic acids, in the setting of viral infections (e.g., influenza, respiratory syncytial virus, and the like), Nielsen, K., et al., Prototype single step lateral flow technology for detection of avian influenza virus and chicken antibody to avian influenza virus. J Immunoassay Immunochem, 2007. 28(4): p. 307-18; Mokkapati, V.
- BinaxNOW pneumococcal urinary antigen test is the BinaxNOW pneumococcal urinary antigen test; this assay evolved after the serum-based platform was shown to be effective, but cumbersome.
- the urinary POC device can be particularly useful when employed in high-risk patients as a POC testing device. Roson, B., et al., Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis, 2004. 38(2): p. 222-6; Weatherall, C., R. Paoloni, and T. Gottling, Point-of-care urinary pneumococcal antigen test in the emergency department for community acquired pneumonia. Emerg Med J, 2008. 25(3): p. 144-8.
- A. fumigatus e.g., galF
- antigens of A. fumigatus are renally concentrated in animal model and are excreted in urine such that the sensitivity and specificity of a urine-based assay may equal or exceed that of serum based testing.
- Urinary detection of antigens would enable development of an easy-to-use POC testing method that would enable frequent testing in the outpatient setting, thus aiding the ability to diagnose and optimize screening strategies employed to detect infection early in the course of disease.
- the presently disclosed subject matter provides a POC test to detect Aspergillus galF-containing antigens in urine.
- Monoclonal antibodies that recognize galactofuranose residues of A. fumigatus galF have been developed and are used in the presently disclosed galF test.
- a standard ELISA format was used as a screen to identify antibodies to use for capture on the immobilized device.
- the identified antibody can be used as a capture antibody with point of care testing device (strip), which can be optimized for conditions to detect galF-antigen (antibody concentration, incubation conditions, and the like).
- dipstick assay means any assay using a dipstick in which sample solution is contacted with the dipstick to cause sample solution to move by capillary action to a capture zone of the dipstick thereby allowing a target antigen in the sample solution to be captured and detected at the capture zone.
- the contact end of the dipstick is contacted with the test solution. If analyte is present in the test solution it travels to the capture zone of the dipstick by capillary action where it is captured by the capture antibody. The presence of analyte at the capture zone of the dipstick is detected by a further anti-analyte antibody (the detection antibody) labelled with, for example, colloidal gold.
- dipstick tests have several advantages. They are easy and cheap to perform, no specialist instruments are required, and the results are obtained rapidly and can be read visually. These tests are, therefore, particularly suited for use in a physician's office, at home, in remote areas, and in developing countries where specialist equipment may not be available. They can be used, for example, to test whether a patient is infected with a disease causing microorganism such as A. fumigatus.
- the targeting agent and labels may simply be added to the test solution and the test solution then contacted with the contact end of the chromatographic strip.
- Such methods are easier to perform than the method disclosed in WO 00/25135 in which two separate wicking steps are required. The results may, therefore, be obtained more rapidly, and yet the sensitivity of analyte detection is higher.
- chromatographic strip is used herein to mean any porous strip of material capable of transporting a solution by capillarity.
- the chromatographic strip may be capable of bibulous or non-bibulous lateral flow, but preferably bibulous lateral flow.
- non-bibulous lateral flow is meant liquid flow in which all of the dissolved or dispersed components of the liquid are carried at substantially equal rates and with relatively unimpaired flow laterally through the membrane as opposed to preferential retention of one or more components as would occur with “bibulous lateral flow.”
- Materials capable of bibulous lateral flow include paper, nitrocellulose, and nylon. A preferred example is nitrocellulose.
- the labels may be bound to the ligands of the targeting agent by pre-mixing the targeting agent with the labels before the targeting agent is added to (or otherwise contacted with) the test solution. However, in some circumstances, it is preferred that the targeting agent and labels are not pre-mixed because such pre-mixing can cause the targeting agent and labels to precipitate. Thus, the targeting agent and the labels may be added separately to (or contacted separately with) the test solution. The targeting agent and the labels can be added to (or contacted with) the test solution at substantially the same time, or in any order.
- the test solution may be pre-incubated with the targeting agent and labels before the test solution is contacted with the contact end of the chromatographic strip to ensure complex formation.
- the optimal time of pre-incubation will depend on the ratio of the reagents and the flow rate of the chromatographic strip. In some cases, pre-incubation for too long can decrease the detection signal obtained, and even lead to false positive detection signals. Thus, it may be necessary to optimize the pre-incubation time for the particular conditions used.
- the presently disclosed subject matter provides a method for diagnosing a microbial infection in a biological sample from a mammalian subject suspected of having, having, or susceptible to having a microbial infection, by detecting the presence of at least one antigen comprising a galF residue in a biological sample of the mammalian subject, the method comprising: (a) treating the biological sample to decrease or minimize human IntL-1 binding of galF residues present in the sample; (b) contacting the treated sample of (a) with at least one antibody specific for at least one antigen comprising a galF residue in an effective amount to produce a detectable amount of antibody-galF antigen complex; and (c) detecting the presence of at least one antibody-galF antigen complex, wherein the detection of the presence of at least one antibody-galF anti
- the present invention provides a method for diagnosing a microbial infection in a biological sample from a mammalian subject suspected of having, having, or susceptible to having a microbial infection by detecting the presence of at least one antigen comprising a galF residue in a biological sample of the mammalian subject, the method comprising: (a) treating the biological sample comprising contacting the sample with a substrate such as a ligand which binds directly to intelectin, or calcium or mono and divalent cations with high affinity, to inhibit hIntL binding of galF residues present in the sample; (b) contacting the treated sample of (a) with at least one antibody specific for at least one antigen comprising a galF residue in an effective amount to produce a detectable amount of antibody-galF antigen complex; and (c) detecting the presence of at least one antibody-galF antigen complex, wherein the detection of the presence of at least one antibody-galF antigen complex is diagnostic of a microbial infection in
- the microbial infection can be selected from the group consisting of a bacterial infection and a fungal infection.
- the bacterial infection is caused by an infection of Streptococcus pneumoniae .
- the microbial infection is a fungal infection caused by an infection of an organism selected from the group consisting of Aspergillus species, Fusarium species, Coccidiodes species, Cryptococcus species, and Histoplasma species.
- the microbial infection is caused by Prokaryotic and Eukaryotic pathogens that produce galF-containing antigens, including but not limited to, Streptococcus species, Pseudomonas species, Nocardia species, Actinomyces species. Zygomycetes and parasites, including but not limited to Leishmania species, and Trypanosoma species.
- At least one antibody specific for at least one antigen comprising a galactofuranose residue is selected from the group consisting of monoclonal antibody 205 (MAb 205) comprising a variable heavy (VH) domain of SEQ ID NO:1 and a variable light (VL) domain of SEQ ID NO:2; monoclonal antibody 24 (MAb 24) comprising a VH domain of SEQ ID NO:3 and a VL domain of SEQ ID NO:4; monoclonal antibody 686 (MAb 686) comprising a VH domain of SEQ ID NO:5 and a VL domain of SEQ ID NO:6; monoclonal antibody 838 (MAb 838) comprising a VH domain of SEQ ID NO:7 and a VL domain of SEQ ID NO:8; and monoclonal antibody 476 (MAb 476) comprising a VH domain of SEQ ID NO:9 and a VL domain of SEQ ID NO:10.
- the biological sample is selected from the group consisting of urine, bronchoalveolar lavage (BAL) fluid, serum, gastrointestinal fluids, blood, and cerebrospinal fluid (CSF).
- BAL bronchoalveolar lavage
- CSF cerebrospinal fluid
- the presently disclosed methods further comprise pre-treating the biological sample before contacting the biological sample with at least one antibody specific for at least one antigen comprising a galactofuranose residue.
- the pre-treating step can include a step selected from the group consisting of filtering, diluting, and concentrating the biological sample, and combinations thereof.
- the Mab476 antibody used in the methods of the present invention is thought to bind to the galF-containing 0-glycan moiety/moieties associated with cellulose (CelA) protein.
- the Mab476 antibody may bind to galF from any origin, including galF that is present on extracellular vesicles shed by the infectious organism.
- the method for treating the sample in step (a) comprises contacting the sample with a substrate which binds Ca′ ions with high affinity.
- substrates which can bind divalent cations with high affinity include, for example, N,N,N′,N′-tetrakis-(2-pyridylmethyl)ethylenediamine (TPEN, membrane-permeable chelator) and diethylenetriaminepentaacetic acid (DTPA, membrane-impermeable chelator), and cation exchange resins such as AG50, Chelex, poly(acrylic acid).
- the method for treating the sample in step (a) comprises contacting the sample with a compound which chelates Ca′ ions with high affinity.
- chelators include, without limitation, ethylenediamine tetraacetic acid (EDTA), Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), 1,2-bis(o-Aminophenoxy)ethane-N,N,N′,N′-tetraacetic Acid (BAPTA), 1-(2-Nitro-4,5-dimethoxyphenyl)-1,2-diaminoethane-N,N,N′,N′-tetraacetic Acid, 4Na, Dimethoxynitrophenamine (DM-Nitrophen), and others.
- EDTA ethylenediamine tetraacetic acid
- EGTA Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N
- the method for treating the sample in step (a) comprises contacting the sample with EDTA and/or EGTA.
- the method for treating the sample in step (a) comprises contacting the sample with a substrate which binds hIntL-1 with high affinity.
- Examples of compounds which bind hIntL-1 include, but are not limited to, glycerol, 3-keto-2-deoxyoctonic acid, D-glycerol-1-phosphate, D-mannoheptose, and other compounds which are bound by hIntL-1.
- the method for treating the sample in step (a) comprises contacting the sample with an antibody specific for hIntL-1.
- the antibody can be rabbit polyclonal IgG anti-hIntL-1 antibody.
- the method for treating the sample in step (a) comprises contacting the sample with one or more compounds which are bound by hIntL-1 with high affinity.
- the method for treating the sample in step (a) comprises contacting the sample with one or more compounds which bind hIntL with high affinity selected from the group consisting of glycerol, 3-Keto-2-deoxyoctonic acid; D-glycerol-1-phosphate, D-mannoheptose, sepharose, sepharose-containing particles (i.e. latex, polystyrene or glass beads, microspheres or gels).
- one or more compounds which bind hIntL with high affinity selected from the group consisting of glycerol, 3-Keto-2-deoxyoctonic acid; D-glycerol-1-phosphate, D-mannoheptose, sepharose, sepharose-containing particles (i.e. latex, polystyrene or glass beads, microspheres or gels).
- the method for treating the sample in step (a) comprises a combination of one or more of the above methods including, for example, treating the sample with a chelator and one or more compounds which are bound by hIntL with high affinity, and an anti-IntL antibody. Any of the above methods can be combined to further prevent hIntL-1 from binding galF in a biological sample.
- the method for treating the sample in step (a) comprises contacting the sample with a desalting column.
- desalting columns are known in the art, including, for example, desalting columns which are pre-packed with polyacrylamide size exclusion resins.
- a “subject” can include a human subject for medical purposes, such as for the treatment of an existing condition or disease or the prophylactic treatment for preventing the onset of a condition or disease, or an animal subject for medical, veterinary purposes, or developmental purposes.
- Suitable animal subjects include mammals including, but not limited to, primates, e.g., humans, monkeys, apes, and the like; bovines, e.g., cattle, oxen, and the like; ovines, e.g., sheep and the like; caprines, e.g., goats and the like; porcines, e.g., pigs, hogs, and the like; equines, e.g., horses, donkeys, zebras, and the like; felines, including wild and domestic cats; canines, including dogs; lagomorphs, including rabbits, hares, and the like; and rodents, including mice, rats, and the like.
- mammals including, but not limited to, primates, e.g., humans, monkeys, apes, and the like; bovines, e.g., cattle, oxen, and the like; ovines, e.g., sheep and the like; cap
- an animal may be a transgenic animal.
- the subject is a human including, but not limited to, fetal, neonatal, infant, juvenile, and adult subjects.
- a “subject” can include a patient afflicted with or suspected of being afflicted with a condition or disease.
- the terms “subject” and “patient” are used interchangeably herein.
- the subject is a human adult suspected of having, having, or susceptible of having a microbial infection.
- the subject is a human child, e.g., a human less than about 19 years of age, suspected of having, having, or susceptible of having a microbial infection.
- diagnosis refers to a predictive process in which the presence, absence, severity or course of treatment of a disease, disorder or other medical condition is assessed. For purposes herein, diagnosis also includes predictive processes for determining the outcome resulting from a treatment.
- diagnosis refers to the determination of whether a sample specimen exhibits one or more characteristics of a condition or disease.
- diagnosis includes establishing the presence or absence of, for example, a target antigen or reagent bound targets, or establishing, or otherwise determining one or more characteristics of a condition or disease, including type, grade, stage, or similar conditions.
- diagnosis can include distinguishing one form of a disease from another.
- the term “diagnosing” encompasses the initial diagnosis or detection, prognosis, and monitoring of a condition or disease.
- prognosis refers to the determination or prediction of the course of a disease or condition.
- the course of a disease or condition can be determined, for example, based on life expectancy or quality of life.
- prognosis includes the determination of the time course of a disease or condition, with or without a treatment or treatments. In the instance where treatment(s) are contemplated, the prognosis includes determining the efficacy of a treatment for a disease or condition.
- the term “risk” refers to a predictive process in which the probability of a particular outcome is assessed.
- the term “monitoring,” such as in “monitoring the course of a disease or condition,” refers to the ongoing diagnosis of samples obtained from a subject having or suspected of having a disease or condition.
- the term “marker” refers to a molecule, including an antigen, such as a polysaccharide, that when detected in a sample is characteristic of or indicates the presence of a disease or condition.
- the presently disclosed subject matter provides a method for diagnosing of a microbial infection in a mammalian subject suspected of having, having, or susceptible to having a microbial infection, wherein the method comprises monitoring a treatment regimen of a microbial infection to determine the efficacy of the treatment regimen.
- the methods disclosed herein can be used with lateral flow devices such as those disclosed in in U.S. patent application Ser. No. 13/511,264, and incorporated by reference herein in its entirety.
- the presently disclosed methods can use a lateral flow device or dipstick assay comprising an immunochromatographic strip test that relies on a direct (double antibody sandwich) reaction.
- this direct reaction scheme is best used when sampling for larger analytes that may have multiple antigenic sites.
- Different antibody combinations can be used, for example different antibodies can be included on the capture (detection) line, the control line, and included in the mobile phase of the assay, for example, as conjugated to gold particles, e.g., gold microparticles or gold nanoparticles.
- kits for diagnosing a microbial infection in a biological sample from a mammalian subject suspected of having, having, or susceptible to having a microbial infection by detecting the presence of at least one antigen comprising a galactofuranose residue in a biological sample of the mammalian subject.
- kits may include all necessary reagents, components, apparatus and instructions for treating the biological sample to inhibit human intelectin (hIntL) binding of galactofuranose residues present in the sample; in an embodiment, the kits may further comprise at least one antibody specific for at least one antigen comprising a galactofuranose residue in an effective amount to produce a detectable amount of antibody-galF antigen complex; in an embodiment, the kit further enables detecting the presence of at least one antibody-galF antigen complex, wherein the detection of the presence of at least one antibody-galF antigen complex is diagnostic of a microbial infection in a mammalian subject.
- hIntL human intelectin
- the kit comprises the use of a lateral flow apparatus, dipstick, assay stick with immunochromatographic detection display, and any such apparatus know to those skilled in the art.
- reagents and/or detection components may be immobilized on the apparatus itself (i.e. on the dipstick).
- reagents for chelating calcium are included in the kit.
- lateral flow refers to liquid flow along the plane of a substrate or carrier, e.g., a lateral flow membrane.
- lateral flow devices comprise a strip (or a plurality of strips in fluid communication) of material capable of transporting a solution by capillary action, i.e., a wicking or chromatographic action, wherein different areas or zones in the strip(s) contain assay reagents, which are either diffusively or non-diffusively bound to the substrate, that produce a detectable signal as the solution is transported to or migrates through such zones.
- such assays comprise an application zone adapted to receive a liquid sample, a reagent zone spaced laterally from and in fluid communication with the application zone, and a detection zone spaced laterally from and in fluid communication with the reagent zone.
- the reagent zone can comprise a compound that is mobile in the liquid and capable of interacting with an analyte in the sample, e.g., to form an analyte-reagent complex, and/or with a molecule bound in the detection zone.
- the detection zone may comprise a binding molecule that is immobilized on the strip and is capable of interacting with the analyte and/or the reagent and/or an analyte-reagent complex to produce a detectable signal.
- Such assays can be used to detect an analyte in a sample through direct (sandwich assay) or competitive binding.
- Examples of lateral flow devices are provided in U.S. Pat. No. 6,194,220 to Malick et al.; U.S. Pat. No. 5,998,221 to Malick et al.; U.S. Pat. No. 5,798,273 to Shuler et al.; and RE38,430 to Rosenstein.
- the presently disclosed methods can be used with an assay comprising a sandwich lateral flow or dipstick assay.
- a sandwich assay a liquid sample that may or may not contain an analyte of interest is applied to the application zone and allowed to pass into the reagent zone by capillary action.
- analyte refers to an antigen comprising a galactofuranose residue.
- the presence or absence of an analyte in a sample is determined qualitatively. In other embodiments, a quantitative determination of the amount or concentration of analyte in the sample is determined.
- the analyte if present, interacts with a labeled reagent in the reagent zone to form an analyte-reagent complex and the analyte-reagent complex moves by capillary action to the detection zone.
- the analyte-reagent complex becomes trapped in the detection zone by interacting with a binding molecule specific for the analyte and/or reagent. Unbound sample can pass through the detection zone by capillary action to a control zone or an absorbent pad laterally juxtaposed and in fluid communication with the detection zone.
- the labeled reagent may then be detected in the detection zone by appropriate means.
- lateral flow devices comprise a sample pad.
- a sample pad comprises a membrane surface, also referred to herein as a “sample application zone,” adapted to receive a liquid sample.
- a standard cellulose sample pad has been shown to facilitate absorption and flow of biological samples, including, but not limited to, urine.
- the sample pad comprises a portion of lateral flow device that is in direct contact with the liquid sample, that is, it receives the sample to be tested for the analyte of interest.
- the sample pad can be part of, or separate from, a lateral flow membrane. Accordingly, the liquid sample can migrate, through lateral or capillary flow, from sample pad toward a portion of the lateral flow membrane comprising a detection zone.
- the sample pad is in fluid communication with the lateral flow membrane comprising an analyte detection zone. This fluid communication can arise through either be an overlap, top-to-bottom, or an end-to-end fluid connection between the sample pad and a lateral flow membrane.
- the sample pad comprises a porous material, for example and not limited to, paper.
- the targeting agent, molecule or other reagent of the diagnostic method may be immobilized on the conjugate pad. In certain embodiments, the targeting agent, molecule or other reagent of the diagnostic method may be present in an alternative format.
- sample refers to any biological sample suspected of containing an analyte for detection or a control sample expected to be substantially free of the analyte of interest.
- the sample comprises a biological fluid of a subject suspected of having, having, or susceptible of having a microbial infection.
- the biological sample is in liquid form, while in other embodiments it can be changed into a liquid form, e.g., by reconstitution in a suitable solvent, e.g., an aqueous solution.
- suitable solvent e.g., an aqueous solution.
- the presently disclosed lateral flow devices are suitable for use with a variety of biological samples including, but not limited to, urine, bronchoalveolar lavage (BAL) fluid, serum, blood, gastrointestinal fluids, and cerebrospinal fluid (CSF).
- BAL bronchoalveolar lavage
- CSF cerebrospinal fluid
- a sample pad is positioned adjacent to and in fluid communication with a conjugate pad.
- a conjugate pad comprises a labeled reagent having specificity for one or more analytes of interest.
- the conjugate pad comprises a non-absorbent, synthetic material (e.g., polyester) to ensure release of its contents.
- a detection conjugate is dried into place on the conjugate pad and only released when the liquid sample is applied to the sample pad. Detection conjugate can be added to the pad by immersion or spraying.
- the detection conjugate comprises an antibody having specificity for a antigen comprising a galactofuranose residue.
- the antibody is selected from the group consisting of monoclonal antibody 205 (MAb 205) comprising a variable heavy (VH) domain of SEQ ID NO:1 and a variable light (VL) domain of SEQ ID NO:2; monoclonal antibody 24 (MAb 24) comprising a VH domain of SEQ ID NO:3 and a VL domain of SEQ ID NO:4; monoclonal antibody 686 (MAb 686) comprising a VH domain of SEQ ID NO:5 and a VL domain of SEQ ID NO:6; monoclonal antibody 838 (MAb 838) comprising a VH domain of SEQ ID NO:7 and a VL domain of SEQ ID NO:8; and monoclonal antibody 476 (MAb 476) comprising a VH domain of SEQ ID NO:9 and a VL domain of SEQ ID NO:10.
- the antibody e.g., a monoclonal antibody (MAb)
- a gold particle e.g., colloidal gold, including gold microspheres, or gold nanoparticles.
- a gold particle e.g., colloidal gold, including gold microspheres, or gold nanoparticles.
- biotinylate the conjugated MAb to take advantage of the strong affinity that biotin has for streptavidin, using Streptavidin-coated microspheres.
- Alternatives include protein A-coated microspheres that bind to Fc region of IgGs. Conditions to define optimal optimization to colloidal gold can be determined, for example, in microtiter wells.
- colloidal gold at 1 OD530 can be added to each well, followed by 10 ⁇ L of 22 mM buffers (MES, HEPES) at variable pH (5.5 to 10, in 0.5 increments).
- Antibodies can be added at concentrations ranging from about 1.25 ⁇ g/1 OD colloid to about 10 ⁇ g/1 OD colloid, incubated for 15 minutes, and then 25 ⁇ L of 1.5 NaCl can be added. Conjugated particles will be stable and pink; the optimal condition that requires the lowest concentration of antibodies can be determined.
- any detection agent used in the present disclosure will be labeled with any “reporter molecule,” so that it is detectable in any detection system, including, but not limited to enzyme (e.g., ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, and luminescent systems. It is not intended that the present invention be limited to any particular detection system or label.
- screening for the target will be accomplished by techniques known in the art (e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), “sandwich” immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immuNIPA-liffusion assays, in situ immunoassays (e.g., using colloidal gold, enzyme or radioisotope labels), Western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays, etc.), complement fixation assays, immunofluorescence assays, color emitting nanoparticles (e.g. quantum dots), protein A assays, and immunoelectrophoresis assays, etc.
- Such methodologies and techniques are known to those skilled in the art.
- the conjugate pad is adjacent to and in fluid communication with a lateral flow membrane.
- Capillary action draws a fluid mixture up the sample pad, through the conjugate pad where an antibody-galF antigen complex is formed, and into the lateral flow membrane.
- Lateral flow is a function of the properties of the lateral flow membrane.
- the lateral flow membrane typically is extremely thin and is hydrophilic enough to be wetted, thereby permitting unimpeded lateral flow and mixture of reactants and analytes at essentially the same rates.
- Lateral flow membranes can comprise any substrate capable of providing liquid flow including, but not limited to, substrates, such as nitrocellulose, nitrocellulose blends with polyester or cellulose, untreated paper, porous paper, rayon, glass fiber, acrylonitrile copolymer, plastic, glass, or nylon. Lateral flow membranes can be porous. Typically, the pores of a lateral flow membrane are of sufficient size such that particles, e.g., microparticles comprising a reagent capable of forming a complex with an analyte, flow through the entirety of the membrane.
- Lateral flow membranes in general, can have a pore size ranging from about 3 ⁇ m to about 100 ⁇ m, and, in some embodiments, have a pore size ranging from about 10 ⁇ m to about 50 ⁇ m. Pore size affects capillary flow rate and the overall performance of the device.
- nitrocellulose has high protein binding.
- cellulose acetate which has low protein binding.
- Lateral flow membranes can comprise one or more substrates in fluid communication.
- a conjugate pad can be present on the same substrate or may be present on separate substrates (i.e., pads) within or in fluid communication with lateral flow membranes.
- the nitrocellulose membrane can comprise a very thin Mylar sheet coated with a nitrocellulose layer.
- Lateral flow membranes can further comprise at least one indicator zone or detection zone.
- indicator zone and “detection zone” are used interchangeably herein and mean the portion of the carrier or porous membrane comprising an immobilized binding reagent.
- binding reagent means any molecule or a molecule bound to a particle, wherein the molecule recognizes or binds the analyte in question.
- the binding reagent is capable of forming a binding complex with the analyte-labeled reagent complex.
- the binding reagent is immobilized in the detection zone and is not affected by the lateral flow of the liquid sample due to the immobilization on the membrane.
- the binding reagent binds the analyte-labeled reagent complex it prevents the analyte-labeled reagent complex from continuing with the flow of the liquid sample.
- the binding reagent is an antibody having specificity for an antigen having at least one galactofuranose residue.
- the first member binds in the indicator zone to the second member and the resulting bound complex is detected with specific antibodies.
- Detection may use any of a variety of labels and/or markers, e.g., enzymes (alkaline phosphatase or horseradish peroxidase with appropriate substrates), radioisotopes, liposomes or latex beads impregnated with fluorescent tags, polymer dyes or colored nanoparticles, and the like.
- the result can be interpreted by any direct or indirect reaction. Colloidal gold particles, which impart a purple or red coloration, are most commonly used currently.
- the capture and immobilization of the assay reagent (complementary member of the binding pair) at the indicator zone can be accomplished by covalent bonding or, more commonly, by adsorption, such as by drying. Such capture also can be indirect, for example, by binding of latex beads coated with the reagent. Depending on the nature of the material comprising the lateral flow membrane, covalent bonding may be enabled, for example with use of glutaraldehyde or a carbodiimide. In immunoassays, most common binding pairs are antigen-antibody pairs; however, multiple other binding pairs can be performed, such as enzyme-substrate and receptor-ligand.
- the indicator zone further comprises a test line and a control line.
- a test line can comprise an immobilized binding reagent.
- antibodies When antibodies are used to develop a test line in the LFD that employs a sandwich type of assay, they are applied at a ratio of about 1-3 ⁇ g/cm across the width of a strip 1 mm wide; hence, antibody concentration is about 10-30 ⁇ g/cm 2 , which is about 25-100 fold that used in an ELISA. Brown, M. C., Antibodies: key to a robust lateral flow immunoassay , in Lateral Flow Immunoassay , H.Y.T. R. C. Wong, Editor. 2009, Humana Press: New York, N.Y. p. 59-74.
- the presently disclosed lateral flow assays can be used to detect multiple analytes in a sample.
- the reagent zone can comprise multiple labeled reagents, each capable of binding to a different analyte in a liquid sample or a single labeled reagent capable of binding to multiple analytes. If multiple labeled reagents are used in a lateral flow assay, the reagents may be differentially labeled to distinguish different types of analytes in a liquid sample.
- the device may be adapted to detect galF and another fungal component to increase the potential spectrum of pathogens detected and to increase specificity of the reaction. Aspergillus species are thought to secrete galF and other fungal components, while glycans from other ‘contaminants’ should not contain other fungal components.
- a lateral flow membrane can include a control zone comprising a control line.
- control zone refers to a portion of the test device comprising a binding molecule configured to capture the labeled reagent.
- the control zone may be in liquid flow contact with the detection zone of the carrier, such that the labeled reagent is captured on the control line as the liquid sample is transported out of the detection zone by capillary action. Detection of the labeled reagent on the control line confirms that the assay is functioning for its intended purpose. Placement of a control line can be accomplished using a microprocessor controlled TLC spotter, in which a dispenser pump releases a constant volume of reagent across the membrane.
- a typical lateral flow device can also comprises an absorbent pad.
- the absorbent pad comprises an “absorbent material,” which as used herein, refers to a porous material having an absorbing capacity sufficient to absorb substantially all the liquids of the assay reagents and any wash solutions and, optionally, to initiate capillary action and draw the assay liquids through the test device.
- Suitable absorbent materials include, for example, nitrocellulose, nitrocellulose blends with polyester or cellulose, untreated paper, porous paper, rayon, glass fiber, acrylonitrile copolymer, plastic, glass, or nylon.
- a lateral flow membrane is bound to one or more substantially fluid-impervious sheets, one on either side, e.g., a bottom sheet and a complimentary top sheet with one or more windows defining an application zone and an indicator zone.
- a typical lateral flow device also can include a housing.
- the term “housing” refers to any suitable enclosure for the presently disclosed lateral flow devices. Exemplary housings will be known to those skilled in the art.
- the housing can have, for example, a base portion and a lid portion.
- the lid portion can include a top wall and a substantially vertical side wall. A rim may project upwardly from the top wall and may further define a recess adapted to collect a sample from a subject.
- Suitable housings include those provided in U.S. Pat. No. 7,052,831 to Fletcher et al and those used in the BD DirectigenTM EZ RSV lateral flow assay device.
- the microbial infection can be selected from the group consisting of a bacterial infection and a fungal infection.
- the bacterial infection is caused by an infection of Streptococcus pneumoniae .
- the microbial infection is a fungal infection caused by an infection of an organism selected from the group consisting Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species and Zygomycetes.
- the microbial infection is caused by an organism having a propensity to cause lung infection, including but not limited to, Streptococcus species, Pseudomonas species, Nocardia species, Actinomyces species, Mycobacteria species as well as fungal organisms such as Aspergillus species, Cryptococcus species, Histoplasma species, and Zygomycetes.
- an antigen having a galactofuranose residue can be measured in whole, unconcentrated, or otherwise unprocessed, biological samples using the presently disclosed methods and devices.
- the biological sample can be processed, e.g., concentrated, diluted, filtered, and the like, prior to performing the test.
- the pre-treatment of the urine sample can include diluting the urine sample in an aqueous solution, concentrating the urine sample, filtering the urine sample, or a combination thereof.
- the pre-treatment steps can be performed in any particular order, e.g., in some embodiments, the sample can be diluted or concentrated and then filtered, whereas in other embodiments, the sample can be filtered and then diluted or concentrated.
- the presently disclosed methods include filtering the urine sample, for example, through a desalting column, to remove an inhibitor that interferes with the detection of antigen in the urine sample. This step can be performed with or without any further dilution or concentration of the sample.
- the lateral flow device further comprises an apparatus adapted to pre-treat the biological sample before contacting the biological sample with at least one antibody specific for at least one polysaccharide comprising a galF residue.
- the apparatus is adapted to filter, dilute, or concentrate the biological sample, or combinations thereof. More particularly, the apparatus can be adapted to remove an inhibitor that interferes with the detection of the at least one antigen comprising a galF residue in the biological sample, in particular, a urine sample.
- the presently disclosed subject matter provides an antibody specific for at least epitope of an antigen secreted by a microbial organism.
- the antigen comprises a galF residue.
- the antibody is specific for at least one epitope of an antigen secreted by a microbial organism selected from the group consisting of Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, Zygomycetes and certain Streptococcus species.
- the antibody is specific for at least one epitope of a polysaccharide secreted by a microbial organism selected from the group consisting of Streptococcus species, Pseudomonas species, Nocardia species, Actinomyces species, Mycobacteria species, Leishmania species and Trypanosoma species
- kits comprising components of a diagnostic regimen, for example components for processing a sample along with a detection assay, lateral flow device, dipstick, and instructions for using the same.
- the kit can also comprise packaging or a container housing at least one or more components of the diagnostic assay, and can also comprise instructions on storage, administration, dosing or the like and/or an insert regarding the active ingredients.
- the kit can also comprise instructions for monitoring the presence and/or prevalence of an infectious organisms (or metabolites thereof) once administered, and optionally, materials for performing such assays including, e.g., reagents, well plates, containers, markers or labels, spin columns, and the like.
- Other suitable components to include in kits of the disclosure will be readily apparent to one of skill in the art, taking into consideration the infectious organism to be detected, sample to be processed, and storage conditions.
- the term “about,” when referring to a value can be meant to encompass variations of, in some embodiments, ⁇ 100% in some embodiments ⁇ 50%, in some embodiments ⁇ 20%, in some embodiments ⁇ 10%, in some embodiments ⁇ 5%, in some embodiments ⁇ 1%, in some embodiments ⁇ 0.5%, and in some embodiments ⁇ 0.1% from the specified amount, as such variations are appropriate to perform the disclosed methods or employ the disclosed compositions.
- the bound IntL was detected by an anti-omentin Rabbit IgG ab (Millipore) diluted 1:1000 in blocking buffer and incubated at 30° C. for 2 h. Wells were again washed and incubated with a goat anti-Rabbit IgG-AP at 1:1000 for 1 h at 30° C. Following another wash, the color was developed by AP substrate for 30 minutes at 37° C.
- Conidia from Aspergillus fumigatus expressing a green fluorescent protein (GFP) were counted and adjusted to 10 6 /mL in Sabouraud's Dextrose broth, and grown for 6 hours at 37° C. to germinate (forming hyphae). The collection of swollen, germinating conidia and growing hyphae from already-germinated conidia were killed with heat at 90° C. for 1 h.
- GFP green fluorescent protein
- the fungal material (killed conidia and hyphae) was pelleted by centrifugation, resuspended in IntL-ELISA blocking buffer, and incubated with 10 ⁇ 7 M rIntL-1 (FLAG-tagged) in presence of 10 ⁇ g/mL of either MAb476 or an irrelevant, isotype control antibody mouse IgM for 2 h at 30° C. Following washes with IntL-ELISA buffer, the material was resuspended in IntL-ELISA blocking buffer and incubated with a 1:50 diluted anti-FLAG tag antibody conjugated to the red fluorochrome phycoerythrin (PE). Again, after washes, the stained material was resuspended in IntL-ELISA blocking buffer, transferred to chamber slides and observed under a fluorescent microscope.
- PE red fluorochrome phycoerythrin
- the inventors performed experiments wherein Aspergillus ethanol precipitate and whole cells (conidia and hyphae) were exposed to rIntL-1 and then a sandwich assay using Rabbit polyclonal antibodies to hIntL and goat anti-rabbit antibodies with a fluorescent ligand were performed in buffer comprising 10 mM CaCl 2 . As shown in FIG. 4 , hIntL bound Aspergillus ethanol precipitate with high affinity in the presence of Ca 2+ . Thus, hIntL could be the competitive agent which is interfering with the inventors' antibodies to galF.
- the PEAKS search confirmed the presence of hIntL sequences in the analyzed 476-reactive eluate, indicating the increased likelihood of hIntL being the protein in the urine which competitively interferes with mAB476, and binds galF antigens.
- the inventors identified IntL-1 as binding to the same Aspergillus derived galF-bearing antigens as mAB476 antibody. Since desalting the urine samples prior to contacting the sample with the galF-reactive antibodies resulted in much greater binding and detection, it was surmised that removal of Ca′ in the samples caused IntL-1 to lose its native ability to bind galF, making free galF much more available to bind the galF-specific antibodies, such as mAB476.
- a galF-binding antibody such as mAB476, was added to the wells diluted in pooled healthy urine (pool 4), untreated or treated with compounds which are known hIntL ligands or Ca′ chelators; the samples with the known ligands or chelators had significantly greater antibody binding compared to the untreated urine, and at the highest antibody concentration, the signal was the same or better than the desalting (positive control for treatment).
- the inventors have developed a successful methodology to overcome hIntL competitive binding without use of extensive pretreatment processing of the urine samples.
Abstract
Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of galactofuranose (galF)-containing antigenic components utilizing monoclonal antibodies. The methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galF antigens and improvement of sensitivity of galF antigen detection assays. The methods include minimizing intelectin-1 binding to galF antigens and improvement of monoclonal antibody binding. The detection methods are useful for identifying the presence of microbial antigens related to bacterial, fungal, and parasitic pathogens, including Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, and Leishmania species.
Description
- This application is a continuation-in-part application of U.S. patent application Ser. No. 14,546,830, filed on Nov. 18, 2014 which is a Continuation of U.S. patent application Ser. No. 13/511,264, filed on Sep. 25, 2012, which is a § 371 application of PCT/US2010/057819, filed Nov. 23, 2010, which claims priority to U.S. Provisional Patent Application No. 61/263,498, filed Nov. 23, 2009, each of which are hereby incorporated by reference for all purposes as if fully set forth herein.
- The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Apr. 6, 2017, is named P10606-06_ST25.txt and is 5,759 bytes in size.
- Galactose is common in mammals, but only found in the 6-member ring hexopyranosyl form, called galactopyranose (galP). Galactofuranose (galF), the 5-member ring form of galactose, is found in other organisms, including bacteria, fungi, protozoa, lichens, green algae, starfish and sponges. Equilibrium strongly favors the galP form unless the organism contains specific enzymes to catalyze maintenance of galF. In these organisms, galF is an important residue on glycoconjugate antigens, and can be found linked to secreted and cellular polysaccharides, glycoproteins and glycosphingolipids. In certain organisms where the galF form is detected, introduction of galF is via inhalation and pulmonary introduction.
- The present inventors previously identified a class of antibodies that were generated against conidia of an important fungal pathogen, called Aspergillus fumigatus. These antibodies were found to identify galF—containing antigens that were quickly excreted in urine after infection in mammals. The antibodies and the technology enable their use as a urine diagnostic assay.
- What is needed however, are methods for improving detection and optimizing the sensitivity of the antibodies, namely improved detection of galF—containing antigens in biological samples such as urine. What is also needed are methods that improve sensitivity and performance of such detection assays with minimal sample processing.
- In accordance with one or more embodiments, the present invention provides methods for improved galF antigen detection in human body fluids by disabling or otherwise removing a competitive inhibitor, the human lectin, intelectin-1 from the assay process previously disclosed in U.S. patent application Ser. No. 13/511,264, and incorporated by reference herein in its entirety. Although intelectin is known to be secreted by epithelial cells lining the GI tract and respiratory tract, and for recognizing galF antigens, intelectin was not known until now to be present in urine. The present inventors surprisingly determined that intelectin is also present in urine, and serves to compete with galF-directed antibodies when they are used as part of diagnosing microbial infections in a mammalian subject. Though not wishing to be bound by the following theory, it is thought that this inhibition or interference is dependent on calcium, which can be removed by chelation as a mechanism to optimize antigen identification.
- In some embodiments, the microbial infection is caused by an organism selected from the group consisting of Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, and Histoplasma species.
- In some embodiments, the microbial infection is caused by Prokaryotic and Eukaryotic pathogens that produce galF-containing antigens, including but not limited to, Streptococcus species, Pseudomonas species, Nocardia species, Actinomyces species. Zygomycetes and parasites, including but not limited to Leishmania species, and Trypanosoma species.
- As such, in accordance with one or more embodiments, the present invention provides methods for optimization of galF-antigen identification in fluids that contain intelectin, including urine, respiratory fluids, gastrointestinal fluids, and blood. The present inventors found that this is important for optimizing those methods that specifically focus on fungal antigens. The utility is broadly applicable to diagnostics that target galF containing antigens in many different diagnostic systems, given the ubiquity of galF in microbial antigens.
- In accordance with an embodiment, the present invention provides a method for diagnosing a microbial infection in a biological sample from a mammalian subject suspected of having, having, or susceptible to having a microbial infection by detecting the presence of at least one microbial molecule comprising a galactofuranose (galF) residue (for example, glycoprotein, polysaccharide or sphingolipid) in a biological sample of the mammalian subject, the method comprising: (a) treating the biological sample to decrease human intelectin (hIntL) binding of galF residues present in the sample; (b) allowing the treated sample of (a) to come in contact with at least one antibody specific for at least one molecule comprising a galF residue in an effective amount to produce a detectable amount of antibody-galF complex; and (c) detecting the presence of at least one antibody-galF complex, wherein the detection of the presence of at least one antibody-galF complex is diagnostic of a microbial infection in a mammalian subject.
- In accordance with another embodiment, the present invention provides a method for diagnosing a microbial infection in a biological sample from a mammalian subject suspected of having, having, or susceptible to having a microbial infection by detecting the presence of at least one antigen comprising a galF residue in a biological sample of the mammalian subject, the method comprising: (a) treating the biological sample comprising contacting the sample with a substrate such as a ligand which binds directly to intelectin, or calcium or divalent cations with high affinity, thereby inhibiting or interfering with human intelectin (hIntL) binding of microbial molecule containing galF residues present in the sample; (b) contacting the treated sample of (a) with at least one antibody specific for at least one molecule comprising a galF residue in an effective amount to produce a detectable amount of antibody-galF complex; and (c) detecting the presence of at least one antibody-galF complex, wherein the detection of the presence of at least one antibody-galF complex is diagnostic of a microbial infection in a mammalian subject.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with a substrate which binds Ca′ ions with high affinity.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with a compound which chelates Ca2+ ions with high affinity.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with EDTA and/or EGTA.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with a substrate which binds hIntL with high affinity.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with an antibody specific for hIntL.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with one or more compounds which are bound by hIntL with high affinity, thereby preventing galF-binding to hIntL.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with one or more compounds which are bound by hInL with high affinity selected from the group consisting of glycerol, 3-Keto-2-deoxyoctonic acid; D-glycerol-1-phosphate, D-mannoheptose, sepharose, sepharose-containing particles (i.e. latex, polystyrene or glass beads, microspheres or gels).
-
FIG. 1 illustrates the inventors' prior discovery of galF antigens in the urine of patients with Aspergillus infection and production of monoclonal antibodies specific for galF antigens, with sensitivity to detect excreted antigens in urine samples. -
FIG. 2 shows intelectin and what is known about lectin molecules. -
FIG. 3 shows the inventors' hypothesis that hIntL was secreted into the urine and was competitively binding to galF antigens in the presence of the inventors' monoclonal antibodies specific for galF, and that desalting removes Ca2+ needed for hIntL to bind galF. -
FIGS. 4A-4B depict (A) recombinant hIntL-1 binds to Aspergillus ethanol precipitate (EP) in an ELISA, and (B) binds to whole cells (conidia and hyphae). -
FIG. 5 shows the presence of hIntL-1 in urine from aspergillosis patient and healthy control. Bands with rabbit anti-IntL antibody seen only in lane from concentrated urine. VU7=aspergillosis patient;Pool 4/P4=healthy control urine; “c” denotes concentrated urine via Amicon (10 kDa MWCO); “ds” denotes treatment with desalting column. The gels were exposed for 5 s to SuperSignal West Pico Chemiluminescent reagent (ThermoFisher Inc.). -
FIG. 6 shows that urine from a patient with invasive Aspergillus infection (aspergillosis) contains a different conformation of hIntL than healthy control urine. Radiograms from Western blots show that the aspergillosis patient urine contains small molecular weight bands which migrate at sizes consistent with subunits of the hIntL-1 heterotrimer protein. Healthy patient urine contains a single 120 kDa band of hIntL, consistent with the intact heterotrimer. -
FIG. 7 shows that galF specific antibody mAB476 binds to the band that co-migrates with that recognized by anti-hIntL and shows that when the aspergillosis patient urine is desalted prior to contacting the urine with the antibody, the amount of antibody binding is increased. Desalting also appears to affect the hIntL heterotrimer protein as more of it is found in small molecular weight bands which are the subunits of hIntL. -
FIG. 8 depicts small to medium molecular weight proteins on SDS-PAGE gel probed with mAB476 at a 1:1000 titer and detected with goat-anti-mouse IgM-HRP at a titer of 1:10,000. The mAB476 antibody binds to these small molecular weight moieties in aspergillosis patient urine, but not in healthy patient urine; these are the galF-containing antigens that are released by the microbe. -
FIG. 9 shows localization of mAB476 antibody-reactive bands relative to the anti-hIntL antibody reactive bands. -
FIG. 10 depicts a reducing SDS-PAGE gels of concentrated urine from healthy (pool 4) and patient (VU7), both normal and desalted, were run and stained with Sypro-Ruby fluorescent protein stain. The small to mid-range molecular weight bands were cut out of the gels and prepared for mass spectrometry analysis. -
FIG. 11 shows graphs depicting immunoprecipation assays using mAB476 in urine samples of urine samples, both normal and desalted. To enrich sample detection of moieties specifically binding to mAB476, urines were incubated with superparamagnetic dynabeads coated with mAB476 and a mouse control antibody. mAB476 reactive material was eluted with 50 mM glycine (pH 2.5-3.0). No mAB476 binding occurred in normal urine. Reactivity to mAB476 eluates was confirmed by sandwich ELISA. Eluates were then run on SDS-PAGE gels to check for band patterns, and in-solution mass spectrometry analysis was performed. Analysis detected both the microbial antigen CelA/Aspf7 (a galF-containing 0-glycan), and the human hIntL protein (FIG. 12 ). -
FIGS. 13 and 14 show that treatment of the patient urine with calcium chelators or other compounds which bind calcium or compete with galF for hIntL-1 binding with high affinity, when added prior to contacting the sample with galF antibodies, significantly improves detection sensitivity. - The following detailed description is exemplary and explanatory and is intended to provide further explanation of the present disclosure described herein. Other advantages, and novel features will be readily apparent to one of ordinary skill in the art from the following detailed description of the present disclosure.
- Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of polysaccharide antigenic components utilizing monoclonal antibodies. The methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galF antigens and improvement of sensitivity of galF antigen detection assays. The methods include minimizing hIntL binding to galF antigens and improvement of monoclonal antibody binding. The detection methods are useful for identifying the presence of microbial antigens related to Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, and Histoplasma species. In some embodiments, the microbial infection is caused by Prokaryotic and Eukaryotic pathogens that produce galF-containing antigens, including but not limited to, Streptococcus species, Pseudomonas species, Nocardia species, Actinomyces species. Zygomycetes and parasites, including but not limited to Leishmania species, and Trypanosoma species.
- Intelectin was previously called ‘omentin’ as it is secreted from adipose cells and epithelial cells. Intelectin binds to molecules that contain sugar residues (such as galF), especially those produced by microbes and other non-mammalian organisms (ex. algae, plants). Intelectin is thought to be involved in host-defense as it is produced by epithelial cells facing the environment, such as those lining the airways and gut.
- The antibody of the presently disclosed methods is, in some aspects, specific for at least one antigen containing a galactofuranose residue and is selected from the group consisting of monoclonal antibody 205 (MAb 205) comprising a variable heavy (VH) domain of SEQ ID NO:1 and a variable light (VL) domain of SEQ ID NO:2; monoclonal antibody 24 (MAb 24) comprising a VH domain of SEQ ID NO:3 and a VL domain of SEQ ID NO:4; monoclonal antibody 686 (MAb 686) comprising a VH domain of SEQ ID NO:5 and a VL domain of SEQ ID NO:6; monoclonal antibody 838 (MAb 838) comprising a VH domain of SEQ ID NO:7 and a VL domain of SEQ ID NO:8; and monoclonal antibody 476 (MAb 476) comprising a VH domain of SEQ ID NO:9 and a VL domain of SEQ ID NO:10. The presently disclosed methods are suitable for use in biological samples selected from the group consisting of urine, bronchoalveolar lavage (BAL) fluid, serum, gastrointestinal fluids, blood, saliva and cerebrospinal fluid (CSF).
- In other embodiments, the presently disclosed subject matter provides a lateral flow device adapted to perform the presently disclosed methods for diagnosing a microbial infection in a biological sample of a mammalian subject suspected of having, having, or susceptible to having a microbial infection.
- In accordance with some embodiments, presently disclosed subject matter provides a dipstick assay to perform the presently disclosed methods for diagnosing a microbial infection in a biological sample of a mammalian subject suspected of having, having, or susceptible to having a microbial infection.
- In yet other embodiments, the presently disclosed subject matter provides an antibody specific for at least epitope of an antigen secreted by a microbial organism, wherein in particular aspects, the antigen comprises a galactofuranose residue.
- The ability to provide test results rapidly to the patient and/or healthcare provider is very important to impact outcomes of multiple conditions. Rapid tests to aid diagnosis and enable early detection of multiple diseases and physiologic conditions are being developed. Such tests are especially useful when they can be applied with self-testing and require little in the way of laboratory processing. Examples of point-of-care (POC) test devices in common use today include pregnancy and fertility tests, as well as assays to follow blood glucose in diabetics. Development of diagnostic tests for infections that use POC testing are especially important in resource-poor settings; for this reason, POC testing has become a new goal to be achieved for infections such as HIV, malaria, and hepatitis. Similarly, POC testing has the potential of impacting clinical outcomes when applied to infections that occur in the outpatient setting, not only by providing indications of disease, but by enabling development of more robust prevention algorithms.
- Commonly used immunoassays in diagnostic and research use include radio-immunoassays and enzyme-linked immunosorbent assays (ELISAs). Many of these elaborately configured immunoassays use monoclonal antibodies (mAbs) that possess the ability to bind specifically to the analyte being tested, thereby enhancing the accuracy of the assay. Various approaches have been described for carrying out enzyme immunoassays. A considerable number of these approaches, starting with the earliest of ELISAs, are solid-phase immunoassays in which the analyte to be detected is bound to a solid matrix directly (Direct ELISA) or indirectly (Sandwich ELISA), in which the analyte is captured on a primary reagent. The choice of the solid matrix depends on procedural considerations. A common matrix is the polystyrene surface of multi-well microtiter plates.
- These types of assays also are amenable to developing POC devices, in which systems can be self-contained so that output is readable by the user. This characteristic is especially useful when collection of a sample to be tested does not require medical intervention (e.g., urine, saliva, or sputum). One device that enables this is the lateral-flow device (LFD). These devices use a multi-layered construction containing both absorbent and non-absorbent components to form a solid-phase. The capture and/or recognition reagents (antigen or antibody) are pre-applied to specific areas within the assembled apparatus and the analyte is allowed to flow through the system to come into contact with reagents. Often, for the purpose of self-containment, the reagent components are added in a dried state so that fluid from the sample re-hydrates and activates them. Conventional ELISA techniques can then be used to detect the analyte in the antigen-antibody complex. In some embodiments, the system can be designed to provide a colorimetric reading for visual estimation of a binary response (‘yes’ or ‘no’), or it can be configured to be quantitative.
- Lateral flow devices are used to detect analytes in multiple body fluids, including serum and urine. To date, these types of devices have seen the most use for detecting circulating endogenous analytes; perhaps the most common use of this type of device is in the ubiquitous POC pregnancy test. Current efforts are being directed toward detecting microbial analytes, including nucleic acids, in the setting of viral infections (e.g., influenza, respiratory syncytial virus, and the like), Nielsen, K., et al., Prototype single step lateral flow technology for detection of avian influenza virus and chicken antibody to avian influenza virus. J Immunoassay Immunochem, 2007. 28(4): p. 307-18; Mokkapati, V. K., et al., Evaluation of UPlink-RSV: prototype rapid antigen test for detection of respiratory syncytial virus infection. Ann N Y Acad Sci, 2007. 1098: p. 476-85; bacterial infections (e.g., S. pneumoniae, Legionella, Mycobacteria), Koide, M., et al., Comparative evaluation of Duopath Legionella lateral flow assay against the conventional culture method using Legionella pneumophila and Legionella anisa strains. Jpn J Infect Dis, 2007. 60(4): p. 214-6.
- One assay that is in use worldwide is the BinaxNOW pneumococcal urinary antigen test; this assay evolved after the serum-based platform was shown to be effective, but cumbersome. The urinary POC device can be particularly useful when employed in high-risk patients as a POC testing device. Roson, B., et al., Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis, 2004. 38(2): p. 222-6; Weatherall, C., R. Paoloni, and T. Gottlieb, Point-of-care urinary pneumococcal antigen test in the emergency department for community acquired pneumonia. Emerg Med J, 2008. 25(3): p. 144-8. This issue is particularly relevant in the context of the presently disclosed subject matter, as the polysaccharides in the pneumococcus capsule have some structural similarity to those of Aspergillus. Kappe, R. and A. Schulze-Berge, New cause for false-positive results with the Pastorex Aspergillus antigen latex agglutination test. J Clin Microbiol, 1993. 31(9): p. 2489-90; Stynen, D., et al., Rat monoclonal antibodies against Aspergillus galactomannan. Infect Immun, 1992. 60(6): p. 2237-45; Swanink, C. M., et al., Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol, 1997. 35(1): p. 257-60.
- Preliminary studies have demonstrated that antigens of A. fumigatus (e.g., galF) are renally concentrated in animal model and are excreted in urine such that the sensitivity and specificity of a urine-based assay may equal or exceed that of serum based testing. Urinary detection of antigens would enable development of an easy-to-use POC testing method that would enable frequent testing in the outpatient setting, thus aiding the ability to diagnose and optimize screening strategies employed to detect infection early in the course of disease. Accordingly, in some embodiments, the presently disclosed subject matter provides a POC test to detect Aspergillus galF-containing antigens in urine. Monoclonal antibodies that recognize galactofuranose residues of A. fumigatus galF have been developed and are used in the presently disclosed galF test.
- A standard ELISA format was used as a screen to identify antibodies to use for capture on the immobilized device. The identified antibody can be used as a capture antibody with point of care testing device (strip), which can be optimized for conditions to detect galF-antigen (antibody concentration, incubation conditions, and the like).
- The term “dipstick assay” as used herein means any assay using a dipstick in which sample solution is contacted with the dipstick to cause sample solution to move by capillary action to a capture zone of the dipstick thereby allowing a target antigen in the sample solution to be captured and detected at the capture zone. To test for the presence of analyte, the contact end of the dipstick is contacted with the test solution. If analyte is present in the test solution it travels to the capture zone of the dipstick by capillary action where it is captured by the capture antibody. The presence of analyte at the capture zone of the dipstick is detected by a further anti-analyte antibody (the detection antibody) labelled with, for example, colloidal gold.
- These dipstick tests have several advantages. They are easy and cheap to perform, no specialist instruments are required, and the results are obtained rapidly and can be read visually. These tests are, therefore, particularly suited for use in a physician's office, at home, in remote areas, and in developing countries where specialist equipment may not be available. They can be used, for example, to test whether a patient is infected with a disease causing microorganism such as A. fumigatus.
- To perform a method of the first aspect of the invention, the targeting agent and labels may simply be added to the test solution and the test solution then contacted with the contact end of the chromatographic strip. Such methods are easier to perform than the method disclosed in WO 00/25135 in which two separate wicking steps are required. The results may, therefore, be obtained more rapidly, and yet the sensitivity of analyte detection is higher.
- The term “chromatographic strip” is used herein to mean any porous strip of material capable of transporting a solution by capillarity. The chromatographic strip may be capable of bibulous or non-bibulous lateral flow, but preferably bibulous lateral flow. By the term “non-bibulous lateral flow” is meant liquid flow in which all of the dissolved or dispersed components of the liquid are carried at substantially equal rates and with relatively unimpaired flow laterally through the membrane as opposed to preferential retention of one or more components as would occur with “bibulous lateral flow.” Materials capable of bibulous lateral flow include paper, nitrocellulose, and nylon. A preferred example is nitrocellulose.
- The labels may be bound to the ligands of the targeting agent by pre-mixing the targeting agent with the labels before the targeting agent is added to (or otherwise contacted with) the test solution. However, in some circumstances, it is preferred that the targeting agent and labels are not pre-mixed because such pre-mixing can cause the targeting agent and labels to precipitate. Thus, the targeting agent and the labels may be added separately to (or contacted separately with) the test solution. The targeting agent and the labels can be added to (or contacted with) the test solution at substantially the same time, or in any order.
- The test solution may be pre-incubated with the targeting agent and labels before the test solution is contacted with the contact end of the chromatographic strip to ensure complex formation. The optimal time of pre-incubation will depend on the ratio of the reagents and the flow rate of the chromatographic strip. In some cases, pre-incubation for too long can decrease the detection signal obtained, and even lead to false positive detection signals. Thus, it may be necessary to optimize the pre-incubation time for the particular conditions used.
- It may be desired to pre-incubate the targeting agent with the test solution before binding the labels to the targeting agent so that the targeting agent can be allowed to bind to analyte in the test solution under optimum binding conditions. Generally, the presently disclosed subject matter provides a method for diagnosing a microbial infection in a biological sample from a mammalian subject suspected of having, having, or susceptible to having a microbial infection, by detecting the presence of at least one antigen comprising a galF residue in a biological sample of the mammalian subject, the method comprising: (a) treating the biological sample to decrease or minimize human IntL-1 binding of galF residues present in the sample; (b) contacting the treated sample of (a) with at least one antibody specific for at least one antigen comprising a galF residue in an effective amount to produce a detectable amount of antibody-galF antigen complex; and (c) detecting the presence of at least one antibody-galF antigen complex, wherein the detection of the presence of at least one antibody-galF antigen complex is diagnostic of a microbial infection in a mammalian subject.
- In accordance with another embodiment, the present invention provides a method for diagnosing a microbial infection in a biological sample from a mammalian subject suspected of having, having, or susceptible to having a microbial infection by detecting the presence of at least one antigen comprising a galF residue in a biological sample of the mammalian subject, the method comprising: (a) treating the biological sample comprising contacting the sample with a substrate such as a ligand which binds directly to intelectin, or calcium or mono and divalent cations with high affinity, to inhibit hIntL binding of galF residues present in the sample; (b) contacting the treated sample of (a) with at least one antibody specific for at least one antigen comprising a galF residue in an effective amount to produce a detectable amount of antibody-galF antigen complex; and (c) detecting the presence of at least one antibody-galF antigen complex, wherein the detection of the presence of at least one antibody-galF antigen complex is diagnostic of a microbial infection in a mammalian subject.
- The microbial infection can be selected from the group consisting of a bacterial infection and a fungal infection. In some embodiments, the bacterial infection is caused by an infection of Streptococcus pneumoniae. In other embodiments the microbial infection is a fungal infection caused by an infection of an organism selected from the group consisting of Aspergillus species, Fusarium species, Coccidiodes species, Cryptococcus species, and Histoplasma species.
- In some embodiments, the microbial infection is caused by Prokaryotic and Eukaryotic pathogens that produce galF-containing antigens, including but not limited to, Streptococcus species, Pseudomonas species, Nocardia species, Actinomyces species. Zygomycetes and parasites, including but not limited to Leishmania species, and Trypanosoma species.
- In particular embodiments, at least one antibody specific for at least one antigen comprising a galactofuranose residue is selected from the group consisting of monoclonal antibody 205 (MAb 205) comprising a variable heavy (VH) domain of SEQ ID NO:1 and a variable light (VL) domain of SEQ ID NO:2; monoclonal antibody 24 (MAb 24) comprising a VH domain of SEQ ID NO:3 and a VL domain of SEQ ID NO:4; monoclonal antibody 686 (MAb 686) comprising a VH domain of SEQ ID NO:5 and a VL domain of SEQ ID NO:6; monoclonal antibody 838 (MAb 838) comprising a VH domain of SEQ ID NO:7 and a VL domain of SEQ ID NO:8; and monoclonal antibody 476 (MAb 476) comprising a VH domain of SEQ ID NO:9 and a VL domain of SEQ ID NO:10.
- One of ordinary skill in the art upon review of the presently disclosed subject matter would appreciate that any biological fluid in which at least one antigen comprising a galactofuranose residue is secreted is suitable for use with the presently disclosed methods. In particular embodiments, the biological sample is selected from the group consisting of urine, bronchoalveolar lavage (BAL) fluid, serum, gastrointestinal fluids, blood, and cerebrospinal fluid (CSF).
- In some embodiments, the presently disclosed methods further comprise pre-treating the biological sample before contacting the biological sample with at least one antibody specific for at least one antigen comprising a galactofuranose residue. The pre-treating step can include a step selected from the group consisting of filtering, diluting, and concentrating the biological sample, and combinations thereof.
- Without being held to any particular theory, the Mab476 antibody used in the methods of the present invention is thought to bind to the galF-containing 0-glycan moiety/moieties associated with cellulose (CelA) protein. As described above, the Mab476 antibody may bind to galF from any origin, including galF that is present on extracellular vesicles shed by the infectious organism.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with a substrate which binds Ca′ ions with high affinity.
- Examples of substrates which can bind divalent cations with high affinity include, for example, N,N,N′,N′-tetrakis-(2-pyridylmethyl)ethylenediamine (TPEN, membrane-permeable chelator) and diethylenetriaminepentaacetic acid (DTPA, membrane-impermeable chelator), and cation exchange resins such as AG50, Chelex, poly(acrylic acid).
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with a compound which chelates Ca′ ions with high affinity. Examples of chelators include, without limitation, ethylenediamine tetraacetic acid (EDTA), Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), 1,2-bis(o-Aminophenoxy)ethane-N,N,N′,N′-tetraacetic Acid (BAPTA), 1-(2-Nitro-4,5-dimethoxyphenyl)-1,2-diaminoethane-N,N,N′,N′-tetraacetic Acid, 4Na, Dimethoxynitrophenamine (DM-Nitrophen), and others.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with EDTA and/or EGTA.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with a substrate which binds hIntL-1 with high affinity.
- Examples of compounds which bind hIntL-1 include, but are not limited to, glycerol, 3-keto-2-deoxyoctonic acid, D-glycerol-1-phosphate, D-mannoheptose, and other compounds which are bound by hIntL-1.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with an antibody specific for hIntL-1. In some embodiments, the antibody can be rabbit polyclonal IgG anti-hIntL-1 antibody.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with one or more compounds which are bound by hIntL-1 with high affinity.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with one or more compounds which bind hIntL with high affinity selected from the group consisting of glycerol, 3-Keto-2-deoxyoctonic acid; D-glycerol-1-phosphate, D-mannoheptose, sepharose, sepharose-containing particles (i.e. latex, polystyrene or glass beads, microspheres or gels).
- In accordance with some embodiments, the method for treating the sample in step (a) comprises a combination of one or more of the above methods including, for example, treating the sample with a chelator and one or more compounds which are bound by hIntL with high affinity, and an anti-IntL antibody. Any of the above methods can be combined to further prevent hIntL-1 from binding galF in a biological sample.
- In accordance with some embodiments, the method for treating the sample in step (a) comprises contacting the sample with a desalting column. Examples of desalting columns are known in the art, including, for example, desalting columns which are pre-packed with polyacrylamide size exclusion resins.
- The subject treated by the presently disclosed methods in their many embodiments is desirably a human subject, although it is to be understood that the methods described herein are effective with respect to all vertebrate species, which are intended to be included in the term “subject.” Accordingly, a “subject” can include a human subject for medical purposes, such as for the treatment of an existing condition or disease or the prophylactic treatment for preventing the onset of a condition or disease, or an animal subject for medical, veterinary purposes, or developmental purposes. Suitable animal subjects include mammals including, but not limited to, primates, e.g., humans, monkeys, apes, and the like; bovines, e.g., cattle, oxen, and the like; ovines, e.g., sheep and the like; caprines, e.g., goats and the like; porcines, e.g., pigs, hogs, and the like; equines, e.g., horses, donkeys, zebras, and the like; felines, including wild and domestic cats; canines, including dogs; lagomorphs, including rabbits, hares, and the like; and rodents, including mice, rats, and the like. An animal may be a transgenic animal. In some embodiments, the subject is a human including, but not limited to, fetal, neonatal, infant, juvenile, and adult subjects. Further, a “subject” can include a patient afflicted with or suspected of being afflicted with a condition or disease. Thus, the terms “subject” and “patient” are used interchangeably herein. In particular embodiments, the subject is a human adult suspected of having, having, or susceptible of having a microbial infection. In other embodiments, the subject is a human child, e.g., a human less than about 19 years of age, suspected of having, having, or susceptible of having a microbial infection.
- The presently disclosed methods can be used to diagnose, for the prognosis, or the monitoring of a disease state or condition. As used herein, the term “diagnosis” refers to a predictive process in which the presence, absence, severity or course of treatment of a disease, disorder or other medical condition is assessed. For purposes herein, diagnosis also includes predictive processes for determining the outcome resulting from a treatment. Likewise, the term “diagnosing,” refers to the determination of whether a sample specimen exhibits one or more characteristics of a condition or disease. The term “diagnosing” includes establishing the presence or absence of, for example, a target antigen or reagent bound targets, or establishing, or otherwise determining one or more characteristics of a condition or disease, including type, grade, stage, or similar conditions. As used herein, the term “diagnosing” can include distinguishing one form of a disease from another. The term “diagnosing” encompasses the initial diagnosis or detection, prognosis, and monitoring of a condition or disease.
- The term “prognosis,” and derivations thereof, refers to the determination or prediction of the course of a disease or condition. The course of a disease or condition can be determined, for example, based on life expectancy or quality of life. “Prognosis” includes the determination of the time course of a disease or condition, with or without a treatment or treatments. In the instance where treatment(s) are contemplated, the prognosis includes determining the efficacy of a treatment for a disease or condition.
- As used herein, the term “risk” refers to a predictive process in which the probability of a particular outcome is assessed. The term “monitoring,” such as in “monitoring the course of a disease or condition,” refers to the ongoing diagnosis of samples obtained from a subject having or suspected of having a disease or condition. The term “marker” refers to a molecule, including an antigen, such as a polysaccharide, that when detected in a sample is characteristic of or indicates the presence of a disease or condition.
- Accordingly, in some embodiments, the presently disclosed subject matter provides a method for diagnosing of a microbial infection in a mammalian subject suspected of having, having, or susceptible to having a microbial infection, wherein the method comprises monitoring a treatment regimen of a microbial infection to determine the efficacy of the treatment regimen.
- In accordance with some embodiments, the methods disclosed herein can be used with lateral flow devices such as those disclosed in in U.S. patent application Ser. No. 13/511,264, and incorporated by reference herein in its entirety. The presently disclosed methods can use a lateral flow device or dipstick assay comprising an immunochromatographic strip test that relies on a direct (double antibody sandwich) reaction. Without wishing to be bound to any one particular theory, this direct reaction scheme is best used when sampling for larger analytes that may have multiple antigenic sites. Different antibody combinations can be used, for example different antibodies can be included on the capture (detection) line, the control line, and included in the mobile phase of the assay, for example, as conjugated to gold particles, e.g., gold microparticles or gold nanoparticles.
- In an embodiment, the present disclosure comprises kits for diagnosing a microbial infection in a biological sample from a mammalian subject suspected of having, having, or susceptible to having a microbial infection by detecting the presence of at least one antigen comprising a galactofuranose residue in a biological sample of the mammalian subject. Such kits may include all necessary reagents, components, apparatus and instructions for treating the biological sample to inhibit human intelectin (hIntL) binding of galactofuranose residues present in the sample; in an embodiment, the kits may further comprise at least one antibody specific for at least one antigen comprising a galactofuranose residue in an effective amount to produce a detectable amount of antibody-galF antigen complex; in an embodiment, the kit further enables detecting the presence of at least one antibody-galF antigen complex, wherein the detection of the presence of at least one antibody-galF antigen complex is diagnostic of a microbial infection in a mammalian subject. In certain embodiments, the kit comprises the use of a lateral flow apparatus, dipstick, assay stick with immunochromatographic detection display, and any such apparatus know to those skilled in the art. In certain embodiments, reagents and/or detection components may be immobilized on the apparatus itself (i.e. on the dipstick). In certain embodiments, reagents for chelating calcium are included in the kit.
- As used herein the term “lateral flow” refers to liquid flow along the plane of a substrate or carrier, e.g., a lateral flow membrane. In general, lateral flow devices comprise a strip (or a plurality of strips in fluid communication) of material capable of transporting a solution by capillary action, i.e., a wicking or chromatographic action, wherein different areas or zones in the strip(s) contain assay reagents, which are either diffusively or non-diffusively bound to the substrate, that produce a detectable signal as the solution is transported to or migrates through such zones. Typically, such assays comprise an application zone adapted to receive a liquid sample, a reagent zone spaced laterally from and in fluid communication with the application zone, and a detection zone spaced laterally from and in fluid communication with the reagent zone. The reagent zone can comprise a compound that is mobile in the liquid and capable of interacting with an analyte in the sample, e.g., to form an analyte-reagent complex, and/or with a molecule bound in the detection zone. The detection zone may comprise a binding molecule that is immobilized on the strip and is capable of interacting with the analyte and/or the reagent and/or an analyte-reagent complex to produce a detectable signal. Such assays can be used to detect an analyte in a sample through direct (sandwich assay) or competitive binding. Examples of lateral flow devices are provided in U.S. Pat. No. 6,194,220 to Malick et al.; U.S. Pat. No. 5,998,221 to Malick et al.; U.S. Pat. No. 5,798,273 to Shuler et al.; and RE38,430 to Rosenstein.
- In some embodiments, the presently disclosed methods can be used with an assay comprising a sandwich lateral flow or dipstick assay. In a sandwich assay, a liquid sample that may or may not contain an analyte of interest is applied to the application zone and allowed to pass into the reagent zone by capillary action. The term “analyte” as used herein refers to an antigen comprising a galactofuranose residue. In certain embodiments the presence or absence of an analyte in a sample is determined qualitatively. In other embodiments, a quantitative determination of the amount or concentration of analyte in the sample is determined.
- The analyte, if present, interacts with a labeled reagent in the reagent zone to form an analyte-reagent complex and the analyte-reagent complex moves by capillary action to the detection zone. The analyte-reagent complex becomes trapped in the detection zone by interacting with a binding molecule specific for the analyte and/or reagent. Unbound sample can pass through the detection zone by capillary action to a control zone or an absorbent pad laterally juxtaposed and in fluid communication with the detection zone. The labeled reagent may then be detected in the detection zone by appropriate means.
- Generally, and without limitation, lateral flow devices comprise a sample pad. A sample pad comprises a membrane surface, also referred to herein as a “sample application zone,” adapted to receive a liquid sample. A standard cellulose sample pad has been shown to facilitate absorption and flow of biological samples, including, but not limited to, urine. The sample pad comprises a portion of lateral flow device that is in direct contact with the liquid sample, that is, it receives the sample to be tested for the analyte of interest. The sample pad can be part of, or separate from, a lateral flow membrane. Accordingly, the liquid sample can migrate, through lateral or capillary flow, from sample pad toward a portion of the lateral flow membrane comprising a detection zone. The sample pad is in fluid communication with the lateral flow membrane comprising an analyte detection zone. This fluid communication can arise through either be an overlap, top-to-bottom, or an end-to-end fluid connection between the sample pad and a lateral flow membrane. In certain embodiments, the sample pad comprises a porous material, for example and not limited to, paper. In certain embodiments the targeting agent, molecule or other reagent of the diagnostic method may be immobilized on the conjugate pad. In certain embodiments, the targeting agent, molecule or other reagent of the diagnostic method may be present in an alternative format.
- The term “sample” as used herein refers to any biological sample suspected of containing an analyte for detection or a control sample expected to be substantially free of the analyte of interest. In particular embodiments, the sample comprises a biological fluid of a subject suspected of having, having, or susceptible of having a microbial infection. In some embodiments, the biological sample is in liquid form, while in other embodiments it can be changed into a liquid form, e.g., by reconstitution in a suitable solvent, e.g., an aqueous solution. The presently disclosed lateral flow devices are suitable for use with a variety of biological samples including, but not limited to, urine, bronchoalveolar lavage (BAL) fluid, serum, blood, gastrointestinal fluids, and cerebrospinal fluid (CSF).
- Typically, a sample pad is positioned adjacent to and in fluid communication with a conjugate pad. A conjugate pad comprises a labeled reagent having specificity for one or more analytes of interest. In some embodiments, the conjugate pad comprises a non-absorbent, synthetic material (e.g., polyester) to ensure release of its contents. A detection conjugate is dried into place on the conjugate pad and only released when the liquid sample is applied to the sample pad. Detection conjugate can be added to the pad by immersion or spraying.
- In particular embodiments, the detection conjugate comprises an antibody having specificity for a antigen comprising a galactofuranose residue. In representative embodiments, the antibody is selected from the group consisting of monoclonal antibody 205 (MAb 205) comprising a variable heavy (VH) domain of SEQ ID NO:1 and a variable light (VL) domain of SEQ ID NO:2; monoclonal antibody 24 (MAb 24) comprising a VH domain of SEQ ID NO:3 and a VL domain of SEQ ID NO:4; monoclonal antibody 686 (MAb 686) comprising a VH domain of SEQ ID NO:5 and a VL domain of SEQ ID NO:6; monoclonal antibody 838 (MAb 838) comprising a VH domain of SEQ ID NO:7 and a VL domain of SEQ ID NO:8; and monoclonal antibody 476 (MAb 476) comprising a VH domain of SEQ ID NO:9 and a VL domain of SEQ ID NO:10. The antibody, e.g., a monoclonal antibody (MAb), can be conjugated to a gold particle, e.g., colloidal gold, including gold microspheres, or gold nanoparticles. For example, it is possible to biotinylate the conjugated MAb to take advantage of the strong affinity that biotin has for streptavidin, using Streptavidin-coated microspheres. Alternatives include protein A-coated microspheres that bind to Fc region of IgGs. Conditions to define optimal optimization to colloidal gold can be determined, for example, in microtiter wells. For example, 100 μL of colloidal gold at 1 OD530 can be added to each well, followed by 10 μL of 22 mM buffers (MES, HEPES) at variable pH (5.5 to 10, in 0.5 increments). Antibodies can be added at concentrations ranging from about 1.25 μg/1 OD colloid to about 10 μg/1 OD colloid, incubated for 15 minutes, and then 25 μL of 1.5 NaCl can be added. Conjugated particles will be stable and pink; the optimal condition that requires the lowest concentration of antibodies can be determined.
- It is contemplated that any detection agent used in the present disclosure will be labeled with any “reporter molecule,” so that it is detectable in any detection system, including, but not limited to enzyme (e.g., ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, and luminescent systems. It is not intended that the present invention be limited to any particular detection system or label. Furthermore, it is contemplated that screening for the target will be accomplished by techniques known in the art (e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), “sandwich” immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immuNIPA-liffusion assays, in situ immunoassays (e.g., using colloidal gold, enzyme or radioisotope labels), Western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays, etc.), complement fixation assays, immunofluorescence assays, color emitting nanoparticles (e.g. quantum dots), protein A assays, and immunoelectrophoresis assays, etc. Such methodologies and techniques are known to those skilled in the art.
- Usually, the conjugate pad is adjacent to and in fluid communication with a lateral flow membrane. Capillary action draws a fluid mixture up the sample pad, through the conjugate pad where an antibody-galF antigen complex is formed, and into the lateral flow membrane. Lateral flow is a function of the properties of the lateral flow membrane. The lateral flow membrane typically is extremely thin and is hydrophilic enough to be wetted, thereby permitting unimpeded lateral flow and mixture of reactants and analytes at essentially the same rates.
- Lateral flow membranes can comprise any substrate capable of providing liquid flow including, but not limited to, substrates, such as nitrocellulose, nitrocellulose blends with polyester or cellulose, untreated paper, porous paper, rayon, glass fiber, acrylonitrile copolymer, plastic, glass, or nylon. Lateral flow membranes can be porous. Typically, the pores of a lateral flow membrane are of sufficient size such that particles, e.g., microparticles comprising a reagent capable of forming a complex with an analyte, flow through the entirety of the membrane. Lateral flow membranes, in general, can have a pore size ranging from about 3 μm to about 100 μm, and, in some embodiments, have a pore size ranging from about 10 μm to about 50 μm. Pore size affects capillary flow rate and the overall performance of the device.
- There are multiple benefits to using nitrocellulose for the primary membrane: low cost, capillary flow, high affinity for protein biding, and ease of handling. Nitrocellulose has high protein binding. Another alternative is cellulose acetate, which has low protein binding. Size dictating surface area dictates membrane capacity (the volume of sample that can pass through the membrane per unit time=length×width×thickness×porosity. Because these variables control the rate at which lateral flow occurs, they can impact sensitivity and specificity of the assay. The flow rate also varies with sample viscosity. Several different sizes and polymers are available for use as microspheres, which migrate down the membrane with introduction of the fluidic sample. The optimal flow rate generally is achieved using spheres that are 1/10 the pore size of the membrane or smaller.
- One skilled in the art will be aware of other materials that allow liquid flow. Lateral flow membranes, in some embodiments, can comprise one or more substrates in fluid communication. For example, a conjugate pad can be present on the same substrate or may be present on separate substrates (i.e., pads) within or in fluid communication with lateral flow membranes. In some embodiments, the nitrocellulose membrane can comprise a very thin Mylar sheet coated with a nitrocellulose layer.
- Lateral flow membranes can further comprise at least one indicator zone or detection zone. The terms “indicator zone” and “detection zone” are used interchangeably herein and mean the portion of the carrier or porous membrane comprising an immobilized binding reagent. As used herein, the term “binding reagent” means any molecule or a molecule bound to a particle, wherein the molecule recognizes or binds the analyte in question. The binding reagent is capable of forming a binding complex with the analyte-labeled reagent complex. The binding reagent is immobilized in the detection zone and is not affected by the lateral flow of the liquid sample due to the immobilization on the membrane. Once the binding reagent binds the analyte-labeled reagent complex it prevents the analyte-labeled reagent complex from continuing with the flow of the liquid sample. In some embodiments, the binding reagent is an antibody having specificity for an antigen having at least one galactofuranose residue.
- Accordingly, during the actual reaction between the analyte and the reagent, the first member binds in the indicator zone to the second member and the resulting bound complex is detected with specific antibodies. Detection may use any of a variety of labels and/or markers, e.g., enzymes (alkaline phosphatase or horseradish peroxidase with appropriate substrates), radioisotopes, liposomes or latex beads impregnated with fluorescent tags, polymer dyes or colored nanoparticles, and the like. Thus, the result can be interpreted by any direct or indirect reaction. Colloidal gold particles, which impart a purple or red coloration, are most commonly used currently.
- The capture and immobilization of the assay reagent (complementary member of the binding pair) at the indicator zone can be accomplished by covalent bonding or, more commonly, by adsorption, such as by drying. Such capture also can be indirect, for example, by binding of latex beads coated with the reagent. Depending on the nature of the material comprising the lateral flow membrane, covalent bonding may be enabled, for example with use of glutaraldehyde or a carbodiimide. In immunoassays, most common binding pairs are antigen-antibody pairs; however, multiple other binding pairs can be performed, such as enzyme-substrate and receptor-ligand.
- In some embodiments, the indicator zone further comprises a test line and a control line. A test line can comprise an immobilized binding reagent. When antibodies are used to develop a test line in the LFD that employs a sandwich type of assay, they are applied at a ratio of about 1-3 μg/cm across the width of a
strip 1 mm wide; hence, antibody concentration is about 10-30 μg/cm2, which is about 25-100 fold that used in an ELISA. Brown, M. C., Antibodies: key to a robust lateral flow immunoassay, in Lateral Flow Immunoassay, H.Y.T. R. C. Wong, Editor. 2009, Humana Press: New York, N.Y. p. 59-74. - Further, in some embodiments, the presently disclosed lateral flow assays can be used to detect multiple analytes in a sample. For example, in a lateral flow assay, the reagent zone can comprise multiple labeled reagents, each capable of binding to a different analyte in a liquid sample or a single labeled reagent capable of binding to multiple analytes. If multiple labeled reagents are used in a lateral flow assay, the reagents may be differentially labeled to distinguish different types of analytes in a liquid sample.
- It also is possible to place multiple lines of capture antibodies on the membrane to detect different analytes. Combinations of antibodies that detect different epitopes of glycans may optimize specificity if it is found that one antibody performs at a low quantitative limit of detection, yet exhibits some degree of nonspecific binding (or binding to urine components in control animals). One possibility is that the device may be adapted to detect galF and another fungal component to increase the potential spectrum of pathogens detected and to increase specificity of the reaction. Aspergillus species are thought to secrete galF and other fungal components, while glycans from other ‘contaminants’ should not contain other fungal components.
- For quality control, typically a lateral flow membrane can include a control zone comprising a control line. The term “control zone” refers to a portion of the test device comprising a binding molecule configured to capture the labeled reagent. In a lateral flow assay, the control zone may be in liquid flow contact with the detection zone of the carrier, such that the labeled reagent is captured on the control line as the liquid sample is transported out of the detection zone by capillary action. Detection of the labeled reagent on the control line confirms that the assay is functioning for its intended purpose. Placement of a control line can be accomplished using a microprocessor controlled TLC spotter, in which a dispenser pump releases a constant volume of reagent across the membrane.
- A typical lateral flow device can also comprises an absorbent pad. The absorbent pad comprises an “absorbent material,” which as used herein, refers to a porous material having an absorbing capacity sufficient to absorb substantially all the liquids of the assay reagents and any wash solutions and, optionally, to initiate capillary action and draw the assay liquids through the test device. Suitable absorbent materials include, for example, nitrocellulose, nitrocellulose blends with polyester or cellulose, untreated paper, porous paper, rayon, glass fiber, acrylonitrile copolymer, plastic, glass, or nylon.
- In some embodiments, a lateral flow membrane is bound to one or more substantially fluid-impervious sheets, one on either side, e.g., a bottom sheet and a complimentary top sheet with one or more windows defining an application zone and an indicator zone.
- A typical lateral flow device also can include a housing. The term “housing” refers to any suitable enclosure for the presently disclosed lateral flow devices. Exemplary housings will be known to those skilled in the art. The housing can have, for example, a base portion and a lid portion. The lid portion can include a top wall and a substantially vertical side wall. A rim may project upwardly from the top wall and may further define a recess adapted to collect a sample from a subject. Suitable housings include those provided in U.S. Pat. No. 7,052,831 to Fletcher et al and those used in the BD Directigen™ EZ RSV lateral flow assay device.
- As with the general method described immediately hereinabove, the microbial infection can be selected from the group consisting of a bacterial infection and a fungal infection. In some embodiments, the bacterial infection is caused by an infection of Streptococcus pneumoniae. In particular embodiments, the microbial infection is a fungal infection caused by an infection of an organism selected from the group consisting Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species and Zygomycetes.
- In some embodiments, the microbial infection is caused by an organism having a propensity to cause lung infection, including but not limited to, Streptococcus species, Pseudomonas species, Nocardia species, Actinomyces species, Mycobacteria species as well as fungal organisms such as Aspergillus species, Cryptococcus species, Histoplasma species, and Zygomycetes.
- In some embodiments, an antigen having a galactofuranose residue can be measured in whole, unconcentrated, or otherwise unprocessed, biological samples using the presently disclosed methods and devices. In other embodiments, the biological sample can be processed, e.g., concentrated, diluted, filtered, and the like, prior to performing the test. The pre-treatment of the urine sample can include diluting the urine sample in an aqueous solution, concentrating the urine sample, filtering the urine sample, or a combination thereof.
- One of ordinary skill in the art upon review of the presently disclosed subject matter would appreciate that the pre-treatment steps can be performed in any particular order, e.g., in some embodiments, the sample can be diluted or concentrated and then filtered, whereas in other embodiments, the sample can be filtered and then diluted or concentrated. In particular embodiments, the presently disclosed methods include filtering the urine sample, for example, through a desalting column, to remove an inhibitor that interferes with the detection of antigen in the urine sample. This step can be performed with or without any further dilution or concentration of the sample.
- Thus, in some embodiments, the lateral flow device further comprises an apparatus adapted to pre-treat the biological sample before contacting the biological sample with at least one antibody specific for at least one polysaccharide comprising a galF residue. In particular embodiments, the apparatus is adapted to filter, dilute, or concentrate the biological sample, or combinations thereof. More particularly, the apparatus can be adapted to remove an inhibitor that interferes with the detection of the at least one antigen comprising a galF residue in the biological sample, in particular, a urine sample.
- In other embodiments, different parameters of the test, e.g., incubation time, can be manipulated to increase sensitivity and/or specificity of the test to eliminate the need for processing the biological sample. Accordingly, in some embodiments, the presently disclosed subject matter provides an antibody specific for at least epitope of an antigen secreted by a microbial organism. In particular embodiments, the antigen comprises a galF residue. In more particular embodiments, the antibody is specific for at least one epitope of an antigen secreted by a microbial organism selected from the group consisting of Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, Zygomycetes and certain Streptococcus species. In additional embodiments, the antibody is specific for at least one epitope of a polysaccharide secreted by a microbial organism selected from the group consisting of Streptococcus species, Pseudomonas species, Nocardia species, Actinomyces species, Mycobacteria species, Leishmania species and Trypanosoma species
- Also provided herein are kits comprising components of a diagnostic regimen, for example components for processing a sample along with a detection assay, lateral flow device, dipstick, and instructions for using the same. The kit can also comprise packaging or a container housing at least one or more components of the diagnostic assay, and can also comprise instructions on storage, administration, dosing or the like and/or an insert regarding the active ingredients. The kit can also comprise instructions for monitoring the presence and/or prevalence of an infectious organisms (or metabolites thereof) once administered, and optionally, materials for performing such assays including, e.g., reagents, well plates, containers, markers or labels, spin columns, and the like. Other suitable components to include in kits of the disclosure will be readily apparent to one of skill in the art, taking into consideration the infectious organism to be detected, sample to be processed, and storage conditions.
- Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this presently described subject matter belongs.
- Following long-standing patent law convention, the terms “a,” “an,” and “the” refer to “one or more” when used in this application, including the claims. Thus, for example, reference to “a subject” includes a plurality of subjects, unless the context clearly is to the contrary (e.g., a plurality of subjects), and so forth.
- Throughout this specification and the claims, the terms “comprise,” “comprises,” and “comprising” are used in a non-exclusive sense, except where the context requires otherwise. Likewise, the term “include” and its grammatical variants are intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that can be substituted or added to the listed items.
- For the purposes of this specification and appended claims, unless otherwise indicated, all numbers expressing amounts, sizes, dimensions, proportions, shapes, formulations, parameters, percentages, parameters, quantities, characteristics, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term “about” even though the term “about” may not expressly appear with the value, amount or range. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are not and need not be exact, but may be approximate and/or larger or smaller as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors known to those of skill in the art depending on the desired properties sought to be obtained by the presently disclosed subject matter. For example, the term “about,” when referring to a value can be meant to encompass variations of, in some embodiments, ±100% in some embodiments ±50%, in some embodiments ±20%, in some embodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified amount, as such variations are appropriate to perform the disclosed methods or employ the disclosed compositions.
- Further, the term “about” when used in connection with one or more numbers or numerical ranges, should be understood to refer to all such numbers, including all numbers in a range and modifies that range by extending the boundaries above and below the numerical values set forth. The recitation of numerical ranges by endpoints includes all numbers, e.g., whole integers, including fractions thereof, subsumed within that range (for example, the recitation of 1 to 5 includes 1, 2, 3, 4, and 5, as well as fractions thereof, e.g., 1.5, 2.25, 3.75, 4.1, and the like) and any range within that range.
- The following examples have been included to provide guidance to one of ordinary skill in the art for practicing representative embodiments of the presently disclosed subject matter. In light of the present disclosure and the general level of skill in the art, those of skill can appreciate that the following examples are intended to be exemplary only and that numerous changes, modifications, and alterations can be employed without departing from the scope of the presently disclosed subject matter. The synthetic descriptions and specific examples that follow are only intended for the purposes of illustration, and are not to be construed as limiting in any manner to make compounds of the disclosure by other methods.
- Recombinant IntL-1 Binds to Aspergillus Ethanol Precipitate and Whole Cells (conidia and hyphae).
- Method for Ethanol Precipitate binding.
- Wells of a microtiter plate were coated with 10 μg/ml of EP antigen and blocked with a blocking buffer containing 0.1% BSA in IntL-ELISA buffer (20 mM HEPES pH7.4; 150 mM NaCl; 10 mM CaCl2; 0.1% Tween-20. Ref: Wesener et al. (2015) Nature Structural & Molecular Biology, 22(8):603). Recombinant human IntL-1 (rIntL-1) was serially diluted tenfold in blocking buffer starting at 10−6 M, and incubated on the EP-coated plate for 2 h at 30° C., followed by washes with IntL-ELISA buffer. The bound IntL was detected by an anti-omentin Rabbit IgG ab (Millipore) diluted 1:1000 in blocking buffer and incubated at 30° C. for 2 h. Wells were again washed and incubated with a goat anti-Rabbit IgG-AP at 1:1000 for 1 h at 30° C. Following another wash, the color was developed by AP substrate for 30 minutes at 37° C.
- Method for Conidia & Hyphae binding.
- Conidia from Aspergillus fumigatus expressing a green fluorescent protein (GFP) were counted and adjusted to 106/mL in Sabouraud's Dextrose broth, and grown for 6 hours at 37° C. to germinate (forming hyphae). The collection of swollen, germinating conidia and growing hyphae from already-germinated conidia were killed with heat at 90° C. for 1 h. The fungal material (killed conidia and hyphae) was pelleted by centrifugation, resuspended in IntL-ELISA blocking buffer, and incubated with 10−7 M rIntL-1 (FLAG-tagged) in presence of 10 μg/mL of either MAb476 or an irrelevant, isotype control antibody mouse IgM for 2 h at 30° C. Following washes with IntL-ELISA buffer, the material was resuspended in IntL-ELISA blocking buffer and incubated with a 1:50 diluted anti-FLAG tag antibody conjugated to the red fluorochrome phycoerythrin (PE). Again, after washes, the stained material was resuspended in IntL-ELISA blocking buffer, transferred to chamber slides and observed under a fluorescent microscope.
- The inventors performed experiments wherein Aspergillus ethanol precipitate and whole cells (conidia and hyphae) were exposed to rIntL-1 and then a sandwich assay using Rabbit polyclonal antibodies to hIntL and goat anti-rabbit antibodies with a fluorescent ligand were performed in buffer comprising 10 mM CaCl2. As shown in
FIG. 4 , hIntL bound Aspergillus ethanol precipitate with high affinity in the presence of Ca2+. Thus, hIntL could be the competitive agent which is interfering with the inventors' antibodies to galF. - Human IntL-1 is Present in Human Urine.
- Studies were performed using urine collected from control patients (pool 4) and patient who had Aspergillus infection (VU7). The samples were run in a reducing SDS polyacrylamide gel electrophoresis (PAGE), and the resolved proteins were transferred to a nylon membrane for performing a Western Blot. Some samples used concentrated urine (denoted by “c”) using an Amicon concentrator or were pretreated by desalting columns (denoted by “ds”). As expected in a reducing SDS-PAGE, IntL (homotrimer in native state) was resolved to its monomeric form (MW range˜25-40 kDa). As shown in
FIG. 5 , hIntL was present in patient urine and could also be detected in healthy controls in the concentrated samples. - Patient Urine Contains a Different Form Of hIntL than Healthy Urine.
- Following up from Example 2, Western blots using enzyme-labeled Rabbit antibody to hIntL-1 along with a chemiluminescent substrate corroborate the fact that recombinant hIntL-1 is a 120 kDa homotrimer of about 40 kDa subunits, as shown by bands generated due to partial and incomplete reduction in the reducing SDS-PAGE. Monomers of native hIntL are known to vary in 25-40 kDa range. Patient urine had significantly higher concentrations (thicker bands) of small molecular weight subunits, whereas healthy urine had monomeric and dimeric subunits in the expected size range (
FIG. 6 ). - galF Specific Antibodies Recognize Certain Proteins in Urine.
- The PEAKS search confirmed the presence of hIntL sequences in the analyzed 476-reactive eluate, indicating the increased likelihood of hIntL being the protein in the urine which competitively interferes with mAB476, and binds galF antigens.
- Testing of Various Methods to Inhibit hIntL Binding to galF Antigens in Patient Urine Samples.
- As shown in
FIG. 11 , the inventors identified IntL-1 as binding to the same Aspergillus derived galF-bearing antigens as mAB476 antibody. Since desalting the urine samples prior to contacting the sample with the galF-reactive antibodies resulted in much greater binding and detection, it was surmised that removal of Ca′ in the samples caused IntL-1 to lose its native ability to bind galF, making free galF much more available to bind the galF-specific antibodies, such as mAB476. It was therefore thought, that pre-treatment of urine samples with compositions or compounds which either bound free mono and divalent cations, or which served as high-affinity hIntL-ligand, would allow the galF specific antibodies bind more of free galF in the samples. - As shown in
FIG. 13 , in an indirect ELISA assay where Aspergillus ethanol precipitate containing galF is bound to the plate wells, a galF-binding antibody, such as mAB476, was added to the wells diluted in pooled healthy urine (pool 4), untreated or treated with compounds which are known hIntL ligands or Ca′ chelators; the samples with the known ligands or chelators had significantly greater antibody binding compared to the untreated urine, and at the highest antibody concentration, the signal was the same or better than the desalting (positive control for treatment). Thus, the inventors have developed a successful methodology to overcome hIntL competitive binding without use of extensive pretreatment processing of the urine samples. - As shown in
FIG. 14 , in a sandwich ELISA where a galF-binding antibody, such as mAB476, is bound to the plate wells as the capture antibody, low concentrations of Aspergillus ethanol precipitate, namely 0.1 and 1 μg/mL, were diluted in urine, untreated or treated with compounds that are known ligands of hIntL, or Ca′ chelators, or a combination thereof, incubated with the same galF-binding antibody mAB476 conjugated to enzyme alkaline phosphatase (AP) as the detection reagent, and finally placed in the mAB476 coated wells. Following further incubation, the bound Ab-Ag-Ab complex was detected via color development using a substrate of AP. It was observed that the samples with the known ligands or chelators had significantly greater antibody binding signal at low antigen concentrations compared to the untreated urine sample. This recapitulates the success of the methodology developed by the inventors to circumvent the hIntL competitive binding without extensive sample pre-treatment for detection of low antigen concentrations. - All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
- The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
- Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims (25)
1-11. (canceled)
12. A method for diagnosing a microbial infection in a human subject suspected of having, having, or susceptible to having a fungal infection by detecting the presence of at least one polysaccharide comprising a galactofuranose residue in a urine sample of the human subject comprising:
a) contacting the urine sample with an antibody which recognizes at least one epitope of a galactofuranose residue of a polysaccharide which is attached to a first agent which renders the antibody detectable on a solid surface, wherein the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide or glycan is selected from the group consisting of monoclonal antibody 205 (MAb 205) comprising a variable heavy (V.sub.H) domain encoded by SEQ ID NO:1 and a variable light (V.sub.L) domain encoded by SEQ ID NO:2; monoclonal antibody 24 (MAb 24) comprising a V.sub.H domain encoded by SEQ ID NO:3 and a V.sub.L domain encoded by SEQ ID NO:4; monoclonal antibody 686 (MAb686) comprising a V.sub.H domain encoded by SEQ ID NO:5 and a V.sub.L domain encoded by SEQ ID NO:6; monoclonal antibody 838 (MAb 838) comprising a V.sub.H domain encoded by SEQ ID NO:7 and a V.sub.L domain encoded by SEQ ID NO:8; and monoclonal antibody 476 (MAb 476) comprising a V.sub.H domain encoded by SEQ ID NO:9 and a V.sub.L domain encoded by SEQ ID NO:10;
b) contacting the urine sample with a lateral flow device on which is immobilized a second agent capable of capturing the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide or glycan when it has reacted with said epitope, wherein the lateral flow device consists of an enzyme-linked immunosorbent assay (ELISA); and
c) detecting a fungal infection in accordance with instructions provided with a kit also containing the antibody and the lateral flow device.
13. The method of claim 1, wherein the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide or glycan is monoclonal antibody 476 (MAb 476) comprising a V.sub.H domain encoded by SEQ ID NO:9 and a V.sub.L domain encoded by SEQ ID NO:10.
14. The method of claim 12 , wherein the first agent is an optically detectable label.
15. The method of claim 14 , wherein the optically detectable label is a latex bead impregnated with a fluorescent tag.
16. The method of claim 12 , wherein the lateral flow device comprises a solid surface along which the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide or glycan attached to the first agent can migrate by capillary action.
17. The method of claim 16 , wherein also immobilized on the lateral flow device is a third agent capable of capturing the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide or glycan when it has not reacted with said epitope.
18. The method of claim 12 , wherein the ELISA comprises a direct ELISA or a sandwich ELISA.
19. The method of claim 12 , wherein a mechanism for removing an inhibitor found in urine samples which interferes with the binding of the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide or glycan to such epitopes is utilized.
20. The method of claim 12 , wherein the diagnosis involves screening the human subject for the risk of developing a fungal infection, or for detecting the presence of a fungal infection.
21. The method of claim 20 , wherein the fungal infection is caused by Aspergillus species.
22. A method for diagnosing a microbial infection related to bacterial, fungal, and parasitic pathogens, including Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, and Leishmania species in an immunocompromised human subject suspected of having, having, or at risk for having a microbial infection by detecting the presence of at least one polysaccharide or glycan comprising a galactofuranose residue in a urine sample of the immunocompromised human subject comprising:
a) obtaining a kit containing a binding molecule which carries the amino acid sequences encoded by both SEQ ID NOS. 1 and 2, or SEQ ID NOS. 3 and 4, or SEQ ID NOS. 5 and 6, or SEQ ID NOS. 7 and 8, or SEQ ID NOS. 9 and 10, recognizes at least one epitope of a galactofuranose residue of a polysaccharide or glycan secreted by a microbe and either carries a detectable label or is accompanied by an additional reagent that carries a detectable label and also carries one epitope of a galactofuranose residue of a polysaccharide secreted by the microbe, a lateral flow device on which is immobilized either the binding molecule or an agent capable of capturing the binding molecule either before or after it has reacted with the epitope, wherein the lateral flow device consists of an enzyme-linked immunosorbent assay (ELISA); and instructions for using the binding molecule and the lateral flow device to diagnose the microbial infection;
b) contacting the urine sample with the binding molecule;
c) contacting the urine sample with the lateral flow device; and
d) detecting the microbial infection.
23. The method of claim 22 , wherein the diagnosis involves screening the human subject for the presence of pathogens related to Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, and Leishmania species.
24. The method of claim 22 , wherein the ELISA comprises a direct ELISA or a sandwich ELISA.
25. The method of claim 22 , wherein the kit further comprises a desalting column for removing the effects of an inhibitor found in urine samples which interferes with the binding of the binding molecule which recognizes at least one epitope of the galactofuranose residue of the polysaccharide or glycan to such epitopes.
26. A method for diagnosing a microbial infection using a biological sample from a mammalian subject suspected of having, having, or at risk for having a microbial infection by detecting the presence of at least one polysaccharide comprising a galactofuranose residue in a biological sample of the mammalian subject, the method comprising:
(a) treating the biological sample to inhibit human intelectin (hIntL) binding of galactofuranose residues present in the sample, wherein the treatment of the biological sample comprises contacting the biological sample with at least one ligand which binds directly to intelectin, or substrates which bind divalent cations with high affinity;
(b) contacting the treated sample of (a) with at least one antibody specific for at least one polysaccharide comprising a galactofuranose residue in an effective amount to produce a detectable amount of antibody-polysaccharide complex, wherein the at least one antibody specific for at least polysaccharide comprising a galactofuranose residue is selected from the group consisting of monoclonal antibody 205 (MAb 205) comprising a variable heavy (V.sub.H) domain encoded by SEQ ID NO:1 and a variable light (V.sub.L) domain encoded by SEQ ID NO:2; monoclonal antibody 24 (MAb 24) comprising a V.sub.H domain encoded by SEQ ID NO:3 and a V.sub.L domain encoded by SEQ ID NO:4; monoclonal antibody 686 (MAb686) comprising a V.sub.H domain encoded by SEQ ID NO:5 and a V.sub.L domain encoded by SEQ ID NO:6; monoclonal antibody 838 (MAb 838) comprising a V.sub.H domain encoded by SEQ ID NO:7 and a V.sub.L domain encoded by SEQ ID NO:8; and monoclonal antibody 476 (MAb 476) comprising a V.sub.H domain encoded by SEQ ID NO:9 and a V.sub.L domain encoded by SEQ ID NO:10;
(c) contacting the biological sample with a lateral flow device on which is immobilized a second agent capable of capturing the antibody specific for at least one epitope of the galactofuranose residue of the polysaccharide or glycan when it has reacted with said epitope, wherein the lateral flow device consists of an enzyme-linked immunosorbent assay (ELISA); and
(d) detecting the presence of at least one antibody-polysaccharide complex, wherein the detection of the presence of at least one antibody-antigen complex is diagnostic of a microbial infection in a mammalian subject.
27. The method of claim 26 , wherein the ELISA comprises a direct ELISA or a sandwich ELISA.
28. The method of claim 26 , wherein in step (a) treating the sample comprises contacting the sample with a substrate.
29. The method of claim 28 , wherein the substrate comprises a polyacrylamide resin and/or a desalting column.
30. The method of claim 29 , wherein the desalting column has a molecular weight cut off of less than 10 kDa, or a molecular weight cut off of 7 kDa.
31. The method of claim 26 , wherein the microbial infection comprises a fungal infection.
32. The method of claim 31 , wherein the fungal infection comprises an infection caused by an organism related to Aspergillus species.
33. The method of claim 26 , wherein the mammal is a human.
34. The method of claim 33 , wherein the human is immunocompromised.
35. The method of claim 26 , wherein the biological sample is urine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/388,733 US20210364515A1 (en) | 2009-11-23 | 2021-07-29 | Optimizing diagnostics for galactofuranose containing antigens |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26349809P | 2009-11-23 | 2009-11-23 | |
PCT/US2010/057819 WO2011063395A2 (en) | 2009-11-23 | 2010-11-23 | Lateral flow device for diagnosing microbial infections |
US201213511264A | 2012-09-25 | 2012-09-25 | |
US14/546,830 US9915657B2 (en) | 2009-11-23 | 2014-11-18 | Lateral flow device for diagnosing microbial infections |
US15/882,278 US10585098B2 (en) | 2009-11-23 | 2018-01-29 | Optimizing diagnostics for galactofuranose containing antigens |
US16/750,720 US11079380B2 (en) | 2009-11-23 | 2020-01-23 | Optimizing diagnostics for galactofuranose containing antigens |
US17/388,733 US20210364515A1 (en) | 2009-11-23 | 2021-07-29 | Optimizing diagnostics for galactofuranose containing antigens |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/750,720 Continuation US11079380B2 (en) | 2009-11-23 | 2020-01-23 | Optimizing diagnostics for galactofuranose containing antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210364515A1 true US20210364515A1 (en) | 2021-11-25 |
Family
ID=62242942
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/882,278 Active US10585098B2 (en) | 2009-11-23 | 2018-01-29 | Optimizing diagnostics for galactofuranose containing antigens |
US16/750,720 Active US11079380B2 (en) | 2009-11-23 | 2020-01-23 | Optimizing diagnostics for galactofuranose containing antigens |
US17/388,733 Abandoned US20210364515A1 (en) | 2009-11-23 | 2021-07-29 | Optimizing diagnostics for galactofuranose containing antigens |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/882,278 Active US10585098B2 (en) | 2009-11-23 | 2018-01-29 | Optimizing diagnostics for galactofuranose containing antigens |
US16/750,720 Active US11079380B2 (en) | 2009-11-23 | 2020-01-23 | Optimizing diagnostics for galactofuranose containing antigens |
Country Status (1)
Country | Link |
---|---|
US (3) | US10585098B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10585098B2 (en) * | 2009-11-23 | 2020-03-10 | The Johns Hopkins University | Optimizing diagnostics for galactofuranose containing antigens |
WO2020214675A1 (en) * | 2019-04-15 | 2020-10-22 | Mycomed Technologies Llc | Methods and compositions using extracellular vesicles for the detection of disease and disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10288611B2 (en) * | 2009-11-23 | 2019-05-14 | The Johns Hopkins University | Lateral flow device for diagnosing microbial infections |
US11079380B2 (en) * | 2009-11-23 | 2021-08-03 | The Johns Hopkins University | Optimizing diagnostics for galactofuranose containing antigens |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3445816C1 (en) | 1984-12-15 | 1986-06-12 | Behringwerke Ag, 3550 Marburg | Flat diagnostic agent |
US4943522A (en) | 1987-06-01 | 1990-07-24 | Quidel | Lateral flow, non-bibulous membrane assay protocols |
NL8800073A (en) | 1988-01-13 | 1989-08-01 | Nederlanden Staat | METHOD FOR DETECTING FUNGI IN FOOD AND BODY LIQUIDS OF HUMANS AND ANIMALS. |
DE69229334T2 (en) | 1991-01-11 | 1999-12-16 | Quidel Corp | ONE-STAGE CROSS-FLOW ANALYZING METHOD AND A NON-SUCTIONABLE CARRIER USED IN IT |
CA2111858A1 (en) | 1991-07-15 | 1993-02-04 | James S. Crowe | Production of antibodies |
US5710005A (en) | 1996-10-29 | 1998-01-20 | Biocode, Inc. | Analyte detection with a gradient lateral flow device |
US5945294A (en) | 1996-11-26 | 1999-08-31 | Heska Corporation | Method to detect IgE |
SE9604815D0 (en) | 1996-12-20 | 1996-12-20 | Pharmacia & Upjohn Ab | A method or diagnosis |
US6319466B1 (en) | 1997-07-16 | 2001-11-20 | Charm Sciences, Inc. | Test device for detecting the presence of a residue analyte in a sample |
AUPO930697A0 (en) | 1997-09-19 | 1997-10-09 | Walter And Eliza Hall Institute Of Medical Research, The | Catalytic antibodies and a method of producing same |
NZ518374A (en) | 1999-09-13 | 2006-09-29 | Equitech Lab Inc | A method for detecting a target analyte in a sample |
EP1104768B1 (en) | 1999-12-02 | 2006-11-29 | Council of Scientific and Industrial Research | Peptide sequences from aspergillus fumigatus for the diagnosis of aspergillosis |
US6528325B1 (en) | 2000-10-13 | 2003-03-04 | Dexall Biomedical Labs, Inc. | Method for the visual detection of specific antibodies in human serum by the use of lateral flow assays |
US20030082533A1 (en) | 2001-01-26 | 2003-05-01 | Henry Yue | Intelectin |
GB2372563A (en) | 2001-02-23 | 2002-08-28 | Conidia Bioscience Ltd | Analysis of hydrocarbon fuel for the presence of microorganisms |
EP1461443A2 (en) | 2001-05-25 | 2004-09-29 | Incyte Genomics, Inc. | Carbohydrate-associated proteins |
US6867004B2 (en) | 2001-12-21 | 2005-03-15 | Focus Technologies, Inc. | Methods of using oxidized fungal antigens in antibody testing |
US7371582B2 (en) | 2002-01-23 | 2008-05-13 | Boditechmed Inc. | Lateral flow quantitative assay method and strip and laser-induced fluorescence detection device therefor |
US20040018556A1 (en) | 2002-07-29 | 2004-01-29 | Cantor Thomas L. | Reagent and method for determination of a substance using an immunoaggregator |
US20050214836A1 (en) | 2002-08-30 | 2005-09-29 | Oncotherapy Science, Inc. | Method of diagnosing ovarian endometriosis |
CN1217192C (en) | 2002-11-21 | 2005-08-31 | 北京博奥生物芯片有限责任公司 | Photoelectrochemical tag, method, instrument and kit for photoelectrochemical analysis |
CN100392385C (en) | 2002-12-03 | 2008-06-04 | 博奥生物有限公司 | Chemical amplification electrochemical detecting method for affinity reaction and agent case thereof |
US20060241288A1 (en) | 2003-06-10 | 2006-10-26 | Ace Biosciences A/S | Extracellular aspergillus polypeptides |
WO2006033662A2 (en) | 2004-02-17 | 2006-03-30 | Binax, Inc. | Methods and kits for detection of multiple pathogens |
US20060019406A1 (en) | 2004-07-23 | 2006-01-26 | Ning Wei | Lateral flow device for the detection of large pathogens |
US7465587B2 (en) | 2004-12-03 | 2008-12-16 | Genzyme Corporation | Diagnostic assay device |
US20060127886A1 (en) | 2004-12-15 | 2006-06-15 | Kaylor Rosann M | Sample-efficient lateral flow immunoassay |
EP1739428A1 (en) | 2005-07-01 | 2007-01-03 | Institut Pasteur | In vitro diagnostic method and kit for an aspergillus infection |
WO2007011221A2 (en) | 2005-07-15 | 2007-01-25 | Universiteit Leiden | Anti fungal screening method |
US20070020711A1 (en) | 2005-07-25 | 2007-01-25 | Wheat L J | Fungal antigen immunoassay |
US20080147031A1 (en) | 2006-12-14 | 2008-06-19 | Long Andrew M | Array of absorbent articles with indicators |
WO2008109833A2 (en) | 2007-03-07 | 2008-09-12 | University Of Florida Research Foundation, Inc. | Polynucleotides and polypeptides identified by iviat screening and methods of use |
JP2011519049A (en) | 2008-04-29 | 2011-06-30 | イミューンエクサイト インコーポレイテッド | Immunomodulatory composition and method of use thereof |
HUP0800722A2 (en) | 2008-11-26 | 2010-05-28 | Debreceni Egyetem | Oligonucleotides for the identification of fungi belonging to the aspergillus genus |
DK2379104T3 (en) | 2008-12-31 | 2018-04-30 | Revance Therapeutics Inc | Injectable botulinum toxin formulations |
CN102439038A (en) | 2009-01-16 | 2012-05-02 | 埃克塞特大学 | Antibody |
WO2012162324A2 (en) | 2011-05-23 | 2012-11-29 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Method of diagnosing and treating an aspergillus species-associated condition |
US10739337B2 (en) | 2011-08-30 | 2020-08-11 | Board Of Trustees Of Michigan State University | Extraction and detection of pathogens using carbohydrate-functionalized biosensors |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
EP2970438A4 (en) | 2013-03-15 | 2016-08-24 | Salimetrics Llc | Melatonin monoclonal antibody, detection, methods and uses thereof |
US10082506B2 (en) | 2014-11-05 | 2018-09-25 | Wisconsin Alumni Research Foundation | Microbial glycans as a target of human intelectin |
-
2018
- 2018-01-29 US US15/882,278 patent/US10585098B2/en active Active
-
2020
- 2020-01-23 US US16/750,720 patent/US11079380B2/en active Active
-
2021
- 2021-07-29 US US17/388,733 patent/US20210364515A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10288611B2 (en) * | 2009-11-23 | 2019-05-14 | The Johns Hopkins University | Lateral flow device for diagnosing microbial infections |
US11079380B2 (en) * | 2009-11-23 | 2021-08-03 | The Johns Hopkins University | Optimizing diagnostics for galactofuranose containing antigens |
Also Published As
Publication number | Publication date |
---|---|
US20180156797A1 (en) | 2018-06-07 |
US20200225224A1 (en) | 2020-07-16 |
US11079380B2 (en) | 2021-08-03 |
US10585098B2 (en) | 2020-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11255854B2 (en) | Signal amplification in lateral flow and related immunoassays | |
EP2909331B1 (en) | Method and device for combined detection of viral and bacterial infections | |
US20200209238A1 (en) | Optimizing diagnostics for galactofuranose containing antigens | |
CN107765002B (en) | Colloidal gold immunochromatography test strip and preparation method and application thereof | |
US20210364515A1 (en) | Optimizing diagnostics for galactofuranose containing antigens | |
US20220206000A1 (en) | Methods and compositions using extracellular vesicles for the detection of disease and disorders | |
JP6808728B2 (en) | Detection of cerebrospinal fluid | |
CN101435819A (en) | Immunity-chromatography test utensil | |
EP3511712B1 (en) | Method for measuring thyroglobulin | |
JP7153545B2 (en) | Immunochromatographic test strip, test substance measurement method and immunochromatographic test kit using the same | |
US20170362631A1 (en) | Method and device for determining the presence of a micro-organism in stools with activated carbon pretreatment | |
EP1580557A1 (en) | Method of examining staphylococcus aureus | |
US6649420B1 (en) | Methods and devices for detecting no-complexed prostate specific I antigen | |
CZ299992B6 (en) | Method for detecting pathogenic organisms in fecal, salivary and secretion specimens and biopsy material | |
US7713515B2 (en) | Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis | |
US20220283172A1 (en) | Reduce discard of kidneys for transplanation after brain death | |
WO2020158811A1 (en) | Method for identifying helicobacter pylori strain and kit for identification | |
US20230314434A1 (en) | Semi-quantitative lateral flow devices | |
KR102124257B1 (en) | Burkholderia pseudomallei diagnostic detection kit using rapid immunochromatography, its specific antibody and antibody-producing cell lines | |
WO2004048976A1 (en) | Method of inspecting staphylococcus aureus | |
CN115280146A (en) | Method for assaying fragment containing human type IV collagen 7S domain and kit for use in the assay method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:JOHNS HOPKINS UNIVERSITY;REEL/FRAME:065777/0665 Effective date: 20211101 |